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STUDY ON CARDIOPROTECTIVE EFFECT OF ENALAPRIL 
IN PATIENTS WITH BREAST CANCER   ON DOXORUBICIN 
CHEMOTHERAPY 
 
AIMS AND OBJECTIVES:- 
To determine the Cardioprotective effect of Angiotensin Converting Enzyme 
Inhibitor, Enalapril on Doxorubicin Induced Cardiotoxicity in breast cancer 
patients.  
METHODOLOGY:- 
   The present study was carried out in the inpatients of Department Medical 
Oncology, Government Rajaji Hospital, Madurai after obtaining Institutional 
Ethical Committee Clearance. 60 female Breast   cancer patients undergoing   
doxorubicin based   chemotherapy were included for the study. Patients with Left 
ventricular ejection fraction (LVEF) >50% were taken in to the study. Patients 
were allocated into two groups 30 in each. All the 60 patients treated with FAC 
Chemotherapy regimen (5-Fluorouracil 500mg/m
2
, Doxorubicin 50mg/m
2
, 
Cyclophosphamide 500mg/m
2
) once in 3 weeks for 6 cycles. Test group received 
Tab. Enalapril 5 mg / once daily at bed time started after the 6
th
 cycle of 
chemotherapy schedule and slowly titrated up to 10 mg once daily and continued 
for 6 months. Cardiac assessment was done by measuring Troponin I level at 
baseline,24 hrs after first dose of chemotherapy and at the end of the chemotherapy 
schedule ( 6
th
 cycle ).  Cardiac function was also evaluated by serial measurement 
of   Left ventricular ejection fraction (LVEF) and Fractional Shortening (FS) by 
echocardiogram at baseline, 3
rd
 cycle, 6th cycle, 6
th
 month and 9
th
 month of the 
study.    
RESULTS:- 
     All the 60 patients were followed up to the end of the study. There was no drop 
out from the study. 23.3% of patients in both the groups showed persistent 
elevation of Troponin I level and those subjects were considered as High risk 
groups.  
     The mean LVEF at 9
th 
month in Enalapril treated and control groups  were 
61.90 ±2.34 & 54.57 ± 5.86 respectively. At the end of 9
th
 month the mean LVEF 
was maintained in Enalapril treated group than in control group from baseline line 
value which is statistically significant ( p < 0.001).  
      The mean FS at 9
th 
month in Enalapril treated and control groups  were 34.07 
±2.21 &  28.97 ± 3.47 respectively. When FS is compared between these two 
groups Enalapril treated group showed significant improvement in FS than in 
control group (P <0.001). 
    Sub clinical toxicity defined as more than 10% reduction of  LVEF  from  its 
baseline value during serial  echocardiogram evalution. At the end of study 36.7% 
& 3.3% of patients showed subclinical cardiotoxicity in control and Enalapril 
group respectively. Cardiac events were significantly higher in control subjects 
than in Enalapril treated subjects. 
CONCLUSION:- 
Thus we conclude that the prognostic role of TnI as an early marker of 
cardiotoxicity to find out the high-risk patients and Prophylactic Enalapril 
administration have been showed to preserve the  left ventricular function  & 
improved cardiac outcome. Thus early treatment with Enalapril seems to prevent 
the development of late cardiotoxicity in patients undergone doxorubicin based 
chemotherapy. 
KEY WORDS:- 
Doxorubicin, Cardiotoxicity, Troponin I, Enalapril, Left ventricular ejection 
fraction, Fractional Shortening. 
 
 
 
                                          INTRODUCTION  
           Breast cancer is the second most common cause of cancer in females 
in India 1, contributing to major cause of morbidity & mortality. Breast 
cancer can be treated by multimodality approaches like surgery, 
radiotherapy, chemotherapy & hormonal therapy. The different types of 
chemotherapy for carcinoma breast vary according to the stage whether 
prior surgery has been done or not. It may be adjuvant, neoadjuvant and 
palliative chemotherapy 2.   
            The drugs commonly used to treat breast cancer include 
cyclophosphamide, methotrexate, doxorubicin, 5 flurouracil, pacletaxel, 
docetaxel, carboplatin, trastuzumumab. Most chemotherapeutic agents are 
reported to cause severe adverse reactions and some of which lead to organ 
damage 3. But these agents cannot be avoided in the treatment of cancer 
though side effects cannot be abolished.  
          Major limitations to the clinical efficacy of chemotherapy have been 
toxicity to the normal tissues of the body and the development of drug 
resistance. In the past decade, better understandings of molecular biology 
and pathways/targets have led to target specific therapy. This has resulted in 
a paradigm shift in the management of many cancers.  
        Doxorubicin has been used as an efficacious antitumor antibiotic for 
many solid and haemopoietic malignancies. Doxorubicin (DOX), is an 
anthracycline    antitumor agent, plays vital role in the management of  
breast cancer. However, dose-dependent increased risk of heart failure and 
dilated cardiomyopathy has restricted its clinical use. Cardiotoxicity may 
compromise the efficacy of chemotherapy and affecting the quality of life & 
survival of the patients undergoing cancer chemotherapy. Risk factors 4 for 
doxorubicin induced cardiotoxicity are  cumulative dose above 550 mg/m2, 
more than 60yrs of age, dosing schedule, mediastinal radiotherapy, previous 
cardiac disease, hypertension, female sex and combined chemotherapy with 
known cardiotoxic agents like cyclophosphamide,trastuzumab etc.  
           Multiple mechanisms may contribute to the development of 
chemotherapy induced cardiotoxicity. However free radicals formation and 
oxidative stress to the heart appears to be an important cause of apoptosis 
and cardiomyocyte damage5. Doxorubicin induced Cardiotoxicity may 
develop during and delayed years after the treatment schedule with 
doxorubicin. Acute cardiotoxicity may manifests as tachyarrhythmia, 
pericarditis, myocarditis and even heart failure, can develop within weeks to 
months following treatment. Chronic cardiotoxicity may manifest as severe 
left ventricular dysfunction, dilated cardiomyopathy and chronic heart 
failure months to years after treatment which is not response to conventional 
treatment and become irreversible. 
       Hence patients undergoing anthracycline treatment need serial 
measurements of  LVEF,  Fractional shortening  by echocardiography 6 
prior to, during and after treatment to assess the left ventricular function and 
cardiotoxicity. Cardiac Troponin I is one of the marker for early myocardial 
insult has been used to monitor doxorubicin induced cardiotoxicity. An 
elevation in plasma troponin I level following cancer chemotherapy may be 
an important tool to predict the poor cardiological outcome in patients with 
breast cancer7. 
        Adjustment in doxorubicin dose is the main approach to prevent the 
development of cardiac dysfunction. A certain number of patients still 
develop severe cardiac dysfunction at doses less than 550 mg/m2. Iron 
chelating agent dexrazoxane and analogues of anthracycline like epirubicin, 
idarubicin has been used to protect patients with evidence of early 
cardiotoxicity at medium doses of doxorubicin. Few studies found that 
dexrazoxane eventhough reduce the cardiotoxicity, may also reduce the 
antitumor efficacy of anthracyclines 8.     
             Angiotensin Converting  Enzyme Inhibitors (ACEI) like 
captopril,enalapril have been traditionally used to delay the deterioration of 
left ventricular function in many different clinical settings including 
doxorubicin induced cardiomyopathy 9. Hence ACE inhibitors may be 
useful in preventing doxorubicin induced cardiotoxicity by minimizing 
oxidative stress 10 and limiting left ventricular remodeling. 
               Many experimental animal model data’s found & suggest that the 
Renin-Angiotensin System (RAS) plays a vital role in the formation and 
progression of doxorubicin-induced cardiotoxicity. Hence ACEIs like 
enalapril has been used to prevent & treat the anthracycline-induced 
cardiotoxicity. So patients, who are more prone to develop cardiotoxicity in 
future after exposure to doxorubicin, could have been prevented by 
prophylactic administration of ACEIs.   
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 AIM AND OBJECTIVES 
 To study the Cardioprotective effect of Enalapril on Doxorubicin 
based chemotherapy in breast cancer patients. 
  To check whether Enalapril has got any protective effect on left 
ventricular function in doxorubicin induced cardiotoxicity. 
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BREAST CANCER 
 
          Cancer is defined as a condition in which class of diseases with  a 
group of cells display undifferentiated, uncontrolled growth, invasion via 
the blood, lymphatic  and  metastasis to the most of the organ of the body. 
The treatment of cancer involves surgery, radiotherapy, chemotherapy, 
immunotherapy and targeted therapy.  
         According to WHO 2012, Global burden increases to 14 million new 
cases and 8 million cancer related deaths in 2012. Lung cancer (13.0%) 
followed by breast cancer (11.9%) are the commonly diagnosed cancers 
across the world. More than 50% of all cancers and death related to the 
cancers in 2012 occurred in developing countries like India and these 
proportions are expected to increase further by 2025 12.Since the 2008 
estimates, the incidence of  breast cancer has been raised  by more than 20% 
and mortality has been raised by 14%. The most  commonly diagnosed 
cancer & the  most common cause of cancer related death among women 
across the world is carcinoma  breast12 , which represents one in four of all 
cancers in women.  
      In India, carcinoma breast is the second most common malignancy 
among women next to cancer cervix. Since it presents as painless lump, 
patients neglect and come to hospital often late. 
 ETIOLOGY AND RISK FACTORS OF BREAST CANCER 13 
Etiology 
Familial in 2-5% cases, BRCA1 & BRCA2 mutations in 50-70%,Li-
Fraumen’s syndrome, ataxia telangiectasia, Cowden’s syndrome, p53 
mutation, Hormone replacement therapy  and oral contraceptive pills intake 
for more than 5 years. 
Risk factors for breast cancer 
Moderate risk 
Florid hyperplasia, solid duct papilloma, Obesity, alcohol, Hormone 
Replacement Therapy, nulliparity, age > 35 years at first birth, early 
menarche and late menopause. 
High risk 
Age more than 60 years,  breast cancer in one side, proliferative benign 
breast diseases like lobular carcinoma in situ and atypical ductal 
hyperplasia14, H/O Ductal carcinoma in situ, mammographic dense breast. 
Very high risk 
Radiation exposure to chest, family H/O breast cancer in first degree 
relatives, family H/O breast and ovarian cancer,BRAC1 & BRCA2 mutation 
carrier or first degree relatives with this mutation14. 
 
 
BREAST CANCER CLASSIFICATION 15 
I. Non-invasive epithelial cancer 
 LCIS - Lobular Carcinoma In Situ  
 DCIS -  Ductal Carcinoma In Situ – solid, papillary & 
comedo 
II. Invasive  epithelial cancer 
 Invasive lobular – 10% 
 Invasive ductal – 70% 
 Medullary carcinoma – 5% 
 Tubular, colloid, cribriform – each 2% 
 Invasive papillary, metaplastic, adenoid cystic – each 1% 
III. Mixed connective tissue and epithelial 
 Phylloides, angiosarcoma 
 
CLINICAL PRESENTATION13,14 
Most women with carcinoma breast will present with lump in the breast 
which is hard, painless and may be associated with indrawing of nipple, 
nipple discharge, ulceration and fungation, axillary / supraclavicular node 
enlargement, chest pain, haemoptysis, bone pain, pathological fractures, 
pleural effusion and ascites. 
 
 
INVESTIGATIONS 13 
Mammography:- Women between 40-49 years-studies should be done every 
12 to 24 months. Annual  mammogram to be done for those >50 years and 
women younger than 50 years of age who are in high-risk group. 
 Ultrasound:- Useful in young female with dense breast in whom 
diagnosis is difficult to interpret. Used to localise impalpable areas of 
breast pathology. 
 CT scan :- aid in clinical staging of malignant processes.  
 MRI :- Best  imaging modality for the breast of women with 
implants. 
 FNAC:- done in palpable mass, mass on mammogram.  
 Biopsy:- Excision & Incision 
 Chest X-ray:- Lung metastasis, pleural effusion 
 Bone scan:- Identify occult osseous metastases  
 Liver  enzymes:- SGOT,SGPT,ALP – For liver metastasis. 
 Hormone receptor status:- ER,PR status- to guide adjuvant therapy. 
 HER-2/neu receptor:- to predict prognosis and has better response to 
adriamycin therapy. 
 Triple assessment:-Combination of physical examination, 
mammography and FNAC will produce a diagnostic accuracy 
approaching 100%.  
 
             Table – 1      BREAST CANCER - TNM STAGING SYSTEM 15 
  TX      Primary cancer could not be assessed 
T0      Absence of evidence of primary cancer 
Tis      Carcinoma in situ 
Tis (DCIS) Ductal carcinoma insitu 
Tis (LCIS)  Lobular carcinoma insitu 
Tis(Paget’s)  Paget’s disease of the nipple without tumor  
T1  Tumor  size 2 cm in greater dimension 
T1mic  Microinvasion 0.1 cm or less in greater dimension 
T1a  Tumor  size >0.1 cm but not >0.5 cm in greater dimension 
T1b  Tumor  size >0.5 cm but not >1 cm in greater dimension 
T1c  Tumor  size >1 cm but not >2 cm in greater dimension 
T2  Tumor  size >2 cm but not >5 cm in greater dimension 
T3  Tumor  size >5 cm in greatest dimension 
T4  Any tumor  size with extension to Skin or chest wall 
   T4a              Extents to chest wall, pectoralis muscle not involved            
T4b         Edema ( peau d’orange), or skin  ulceration     
T4c             Both T4a and T4b  
T4d           Inflammatory carcinoma 
   
 Table – 2    Regional lymph nodes—Clinical (N) 
 
N0 No regional lymph node metastasis 
N1 Axillary nodes- ipsilateral,mobile,discrete 
N2a Axillary nodes- ipsilateral fixed  
N2b Metastasis to  I/L internal mammary nodes only 
N3a Metastasis to  I/L infraclavicular  & Axillary nodes 
N3b Metastasis to I/L internal mammary & Axillary nodes 
N3c     Metastasis to I/L supraclavicular lymph nodes 
 
   
                           Table – 3     Distant metastasis (M) 
 
MX Couldnot  be assess the distant metastasis 
M0 Absence of  distant metastasis 
M1 Presence of distant metastasis 
 
 
 
 
                 Table – 4    TNM Stage Groupings15 
Stage 0 TisN0M0     
Stage I T1N0M0     
Stage IIa T0N1M0 T1N1M0 T2N0M0   
Stage IIb T2N1M0 T3N0M0    
Stage IIIa T0N2M0 T1N2M0 T2N2M0 T3N1M0 T3N2M0 
Stage IIIb T4N0M0 T4N1M0 T4N2M0   
Stage IIIc AnyT N3M0     
Stage IV AnyT,Any N,M1     
 
Treatment options in Carcinoma of Breast 14,16 
Pimary - Surgery 
 Lumpectomy - Wide local excision  
 Simple/total mastectomy 
 MRM - Modified Radical Mastectomy 
 Radical mastectomy 
 Axillary lymph node dissection 
Adjuvant  
A. Radiotherapy 
 Post operative radiotherapy & Palliative radiotherapy 
B. Systemic therapy 
 Hormonal therapy – Tomoxifen, Raloxifene, Letrozole. 
 Chemotherapy 
       In 1960s first trails of combination chemotherapy were initiated for 
breast cancer management. First adjuvant chemotherapy was administered 
to women with positive nodes; later in 1980s the use was extended to node 
negative women as well. 
Indications for chemotherapy 13,15 
      The proportional reduction in recurrences and mortality in both node 
positive and negative patients are similar, but given the better prognosis of 
node negative patients especially those node negative with small tumors(<1 
cm). Younger females have proportionally greater reduction in both 
mortality and recurrence than older females with carcinoma breast. 
Combination chemotherapy has been more effective than single agent 
therapy. 
DOSAGE AND SCHEDULE 
Choosing the regimen 
       There is no single regimen that has emerged as the treatment of choice. 
Several trials have demonstrated that a 10% - 20% higher response rate has 
been observed with Doxorubicin/Epirubicin containing regimen with rise in 
median survival from 12-18 months and rise in median time of treatment 
failure from 4 to 6 months.  
 
 
REGIMENS 14,16 
FAC:-5 Fluorouracil:  500mg/m2, Adriamycin: 50mg/m2, 
Cyclophosphamide: 500mg/m2,  On day one & every 3 weeks for 6 cycles. 
AC:-Adriamycin: 60mg/m2, Cyclophosphamide: 600 mg/m2 - 4 cycles are 
given, once in every 3 weeks. 
CMF:-Cyclophosphamide: 750 mg/m2, Methotrexate: 50 mg/m2,5-FU: 600 
mg/m2- Given once in every 3 weeks, for 6 cycles. 
FEC:-5 FU 500mg/m2,Epirubicin 50mg/m2,Cyclophosphamide 500mg/m2- 
On day one &  every 3 weeks for 6 cycles. 
TIMING OF TREATMENT 15,16 
Adjuvant therapy:- (ACT) 
        Chemotherapy   is given after a surgery for cure with an aim to prevent 
local and systemic relapse by eradicating micrometastasis and to improve 
outcome in cancers like breast, ovary, colon etc.  
Neo-adjuvant therapy (NACT) 
         Tumor down staging with NACT is used to convert inoperable tumor 
into operable one and to allow breast conservation surgery. Traditionally, 
neo adjuvant chemotherapy (NACT) has been used in locally advanced 
breast cancers that are inoperable.  
 
 
Palliative therapy 
Depending on the receptor status, distant sites and those experiencing 
distant relapse after adjuvant treatment are treated by palliative measures 
either by endocrine manipulation or chemotherapy. Patients who are 
candidates for chemotherapy are those who fail hormonal therapy or 
presence of visceral metastasis. 
                                 
                                   CANCER CHEMOTHERAPY 
Chemotherapy, which includes newly developed targeted treatments, is the 
principle tool to treat most cancers. The development of effective 
combination chemotherapy for Hodgkin’s lymphoma, childhood leukemia 
and lymphomas in the 1960s provided curative therapeutic strategies for 
patients with advanced malignancies of all types.  
Historical perspective 
     Paul Ehrlich coined the term chemotherapy. Alkylating agents represent 
the first class of chemotherapeutic drugs to be used in the clinical setting. 
First clinical use of nitrogen mustard in a patient with non–Hodgkin’s 
lymphoma was in 1942.  
 
 
Clinical application of chemotherapy 17 
Chemotherapy is used in four main clinical settings:-  
(a) Primary induction treatment for advanced cancers for which there are no 
other effective treatment. (b) As the primary or neoadjuvant treatment for 
patients with localized disease for which local forms of therapy, such as 
surgery, radiation, or both, are ineffective by themselves. (c) Adjuvant 
treatment for early-stage disease following local modes of treatment like 
radiotherapy, surgery or both. (d) Directly instilled into sites of specific 
regions of the body directly affected by the cancer. 
Primary Chemotherapy:  
Cancers for which chemotherapy is a primary treatment  modality in cancers 
like Acute leukemia, Non-Hodgkin lymphoma, Myeloma, Hodgkin 
lymphoma, Germ cell cancer, Lymphoma, Ovarian cancer, Small cell lung 
cancer, Wilms tumor and Embryonal rhabdomyosarcoma. 
Neoadjuvant Chemotherapy:  
Cancers for which neoadjuvant chemotherapy is indicated for locally 
advanced diseases like Non–small cell lung cancer, Head and neck cancer, 
Bladder cancer, Ovarian cancer, Breast cancer. 
Adjuvant Chemotherapy: Cancers for which adjuvant therapy is indicated 
after surgery in Pancreatic cancer, Melanoma, Breast cancer, Non–small cell 
lung cancer, Osteogenic sarcoma, Colorectal cancer, Gastric cancer and 
Anaplastic astrocytoma. 
 
Principles of cancer cell kinetics 2,17 
              The antineoplastic agents follow the logarithmic cell-kill kinetics to 
exert their cytotoxic effects. Constant fraction of cells not numbers are 
killed by these drugs. If  a anticancer agent leads to a 4 log kill of neoplastic 
cells and reduces the tumor burden from 1012 to 108 cells, the same dose is 
used at a tumor burden of 107 cells reduces the tumor mass to 103. Cell kill 
is therefore proportional, regardless of tumor burden. 
  
 
   CLASSIFICATION OF ANTI NEOPLASTIC AGENTS 18 
         The compounds used in the chemotherapy of neoplastic disease are 
quite differed in molecular structure and mode of action, including 
antimetabolites, purine and pyrimidine; alkylating agents; products of 
natural source; hormones and hormonal antagonists; and a variety of agents 
directed at specific molecular targets.                         
 
 
Table – 5     ALKYLATING AGENTS 
Type of agent Individual Drugs 
Nitrogen mustards Chlorambucil, Mechlorethamine, 
Melphalan, Ifosfamide, 
Cyclophosphamide.  
Methylhydrazine derivatives Procarbazine  
Triazenes Temozolomide, Dacarbazine 
Nitrosoureas Streptozocin, Carmustine, Bendamustine 
Alkyl sulfonate Busulfan 
Platinum complexes Cisplatin, oxaliplatin, carboplatin.  
 
Table – 6    ANTIMETABOLITES 
Type of agent Individual Drugs 
Folate  analogs Pemetrexed, Methotrexate  
Purine analogs Pentostatin, Fludarabine, 6-Mercaptopurine ,  
Clofarabine, Nelarabine  
Pyrimydine analogs Gemcitabine, capecitabine, 5-fluorouracil,  
Cytarabine, 5-aza-cytidine 
 
 
Table - 7    NATURAL PRODUCTS 
Type of agent Individual Drugs 
Vinca alkaloids Vinblastine, Vinorelbine, Vincristine 
Antibiotics  Doxorubicin, Daunorubicin, Dactinomycin 
Epipodophyllotoxins Teniposide, Etoposide 
Camptothecins irinotecan ,Topotecan 
Taxanes Paclitaxel, docetaxel 
Echinocandins Yondelis 
Anthracenediones Bleomycin, Mitoxantrone, Mitomycin C 
Enzymes L-Asparaginase 
 Table - 8      HORMONES AND ANTAGONISTS 
Type of agent Individual Drugs 
Adrenocortical Mitotane  
Adrenocortico-steroids Prednisone  
Progestins Medroxyprogesterone acetate, 
Hydroxyprogesterone caproate,  Megestrol 
acetate 
Estrogens  Ethinyl estradiol , Diethylstilbestrol 
Anti-estrogens Toremifene , Tamoxifen,  
Aromatase inhibitors Anastrozole, Letrozole, Exemestane 
Androgens Fluoxymesterone, Testosterone propionate 
Anti-androgen Casodex , Flutamide 
GnRH analog  Leuprolide 
                          
             
Table – 9    MISCELLANEOUS AGENTS 
Type of agent Individual Drugs 
Substituted urea Hydroxyurea 
Differentiating agents Tretinoin, Arsenic trioxide, vorinostat 
Tyrosine  kinase  
inhibitors 
Gefitinib, Imatinib, Dasatinib, Nilotinib, 
Erlotinib Sorafenib, Sunitinib, Lapatinib 
Proteasome inhibitor Bortezomib 
Biological response 
modifiers 
Interleukin-2, Interferon-α 
Immunomodulators Thalidomide, Lenalidomide 
Monoclonal antibodies Temsirolimus, everolimus 
 
 
                                     
                              THE CELL CYCLE 19 
 
Many cytotoxic agents act by damaging DNA. Their toxicity is greatest 
during the S, or DNA synthetic phase of the cell cycle. Others, vinca 
alkaloids and taxanes, block the formation of a functional mitotic spindle in 
the M phase. These agents are most effective on cells entering mitosis, the 
most vulnerable phase of the cell cycle. All cells display a similar pattern of 
cell cycle progression.  
 Phase  that precedes DNA synthesis (G1)  
 DNA synthetic phase (S)  
 An  interval  which is followed by  the termination of DNA synthesis 
(G2)  
 The  mitotic phase (M) in which the cell, containing a double 
complement of DNA, divides into two daughter G1 cells a probability 
of moving into a quiescent state (G0) and failing to move forward for 
long periods of time. 
                                        
                                        Figure – 1   Cell cycle18 
  
 
 
CELL CYCLE SPECIFICITY OF ANTINEOPLASTIC AGENTS 20 
         Slowly growing tumors with a small growth fraction (e.g., carcinomas 
of the colon or non–small cell lung cancer) are less responsive to cycle-
specific drugs. More effective are agents that inflict high levels of DNA 
damage (e.g., alkylating agents) or those that remain at high concentrations 
inside the cell for extended periods of time (e.g., fluoropyrimidines). 
 
                                       DOXORUBICIN 
      Doxorubicin otherwise known as Adriamycin was the first anthracycline 
isolated from Streptomyces peucetius 21 in the year 1963 by both Italian and 
French group of scientists. Italian group isolated natural product 
doxorubicin from Streptomyces peucetius var. caesius. The French group 
produced semi synthetic derivatives. Epirubicin and Idarubicin are analogs 
of daunorubicin and doxorubicin respectively, only slightly differ in their 
chemical structures. Doxorubicin exerts broad-spectrum activity against 
solid human cancers. These drugs have the ability to produce free radicals 
and cause an irreversible, unusual cardiomyopathy which is related to 
exposure of the total dose of the drug.  
CHEMISTRY 
The anthracyclines have a tetra cyclic ring structure attached to 
daunosamine which is an unusual sugar. These  drugs having quinone and 
hydroxyquinone moieties on neighbor rings which permit the loss and gain 
of electrons. Their chemical structures differ from daunorubicin by only a 
single hydroxyl group on Carbon -14. 
 
 
Figure – 2  Chemical Structure of Doxorubicin21 
            
 
Absorption, fate, and excretion20 
      Doxorubicin is very poorly absorbed and is therefore administered 
parenterally. It is relatively rapidly distributed throughout the body 
including breast milk and bound to plasma proteins moderately. There is no 
evidence that it crosses the placenta but it may cause harm to the fetus. 
Doxorubicin is cleared  by complex hepatic metabolism and excrete via bile.               
The plasma disappearance curve is triphasic, with the  first    phase t1/2     
10-20 mts
  
due to distribution, the second phase 1.5  - 10 hrs largely to 
metabolism and last phase due to release from binding sites such as DNA 
and cardiolipin with a terminal t1/2 of 24-48 hrs. 
           Doxorubicin is converted into an alcohol intermediate 22 which plays 
a different role in its therapeutic activity. The drug rapidly enters the lungs, 
heart, liver, spleen and kidneys. It does not cross the blood-brain barrier. 
Doxorubicin is eliminated by its metabolic conversion into aglycones and 
few inactive products. Idarubicin is mainly metabolized into idarubicinol 
that accumulates in plasma and which is responsible of its activity. In the 
presence of hepatic failure the clearance of anthracyclines and their active 
alcohol metabolites are delayed. 50% of initial dose reduction should be 
considered in patients if  serum bilirubin level is elevated. 
FDA approved indications of doxorubicin18 
        Hodgkin' s lymphoma,  ALL , AML, CLL, Non Hodgkin' s lymphoma, 
Multiple myeloma, Mycosis fungoides, Mantle cell lymphoma,  Kaposi 
sarcoma, Breast cancer (adjuvant  and  advanced  disease), Advanced 
Prostate cancer, Gastric cancer, Ewing's sarcoma, Thyroid cancer. In 
combination with cyclophosphamide, it is an important component of 
different regimens used as adjuvant chemotherapy and in metastatic 
carcinoma of the breast 19.  
 
 
 
Mechanism of action 18,20 
        Anthracyclines are directly affecting the transcription and replication 
of  the  neoplastic  cells  by  intercalating with DNA. Their important action 
is mediated by their ability to form a tripartite complex with DNA and 
topoisomerase II. Topoisomerase II is an ATP-dependent enzyme that binds 
to DNA. It causes double-strand nicks at the 3'-phosphate backbone and 
allowing strand passage and uncoiling of super-coiled DNA. Then 
topoisomerase II religates the DNA strands. This enzymatic function is 
important for DNA replication and repair. The tripartite complex formation 
with anthracyclines or with etoposide inhibits the re-ligation of the broken 
DNA strands, which leads to apoptosis. Any defect in DNA double-strand 
break repair sensitizes neoplastic cells to damage by these drugs. But over 
expression of transcription-linked DNA repair may lead to drug resistance. 
        Anthracyclines generates   free radicals in solution and in both normal 
and malignant tissues because of their quinone moieties. Anthracyclines can 
form semiquinone radical intermediates 22 that can react with O2 to produce 
superoxide anion radicals which is responsible of their antitumor activity 
and also its cardiotoxicity. 
        
Figure-3    Mechanism  of  action  of  doxorubicin                           
 
      These can produce both hydroxyl radicals and hydrogen peroxide which 
disrupt DNA and oxidize DNA bases. Iron interacts with doxorubicin and 
stimulates the free radicals production significantly. Catalase and 
superoxide dismutase are defensive enzymes that protect cardiac cells 
against the anthracyclines toxicity. These defense mechanisms may be 
augmented by exogenous administration of antioxidants such as alpha 
tocopherol. Dexrazoxane an iron chelating agent which protects against 
cardiotoxicity. Anthracyclines exposure to the myocardial cells to leads to 
apoptosis. This process is mediated by p53 – a DNA-damage sensor and 
proteases, activated caspases, ceramide, and the Fas receptor-ligand system 
also have been implicated. 
Dosage and administration 22 
         Doxorubicin is usually given as a single intravenous infusion dose of 
60-75 mg/m2 slowly over 4 to 5 minutes that is repeated after 3 weeks. 
Since it is a vesicant, care must be taken to avoid extravasations, tissue 
necrosis. Drug can be given as a continuous infusion over 2-4 days through 
central venous access line. Dose reduction is needed in patients with liver 
failure. Reduce 50% of dose if serum bilirubin between 1.2 – 3.0 mg/dl 22. 
Infuse only 25% of dose if sr.bilirubin level greater than 3 mg/dl. Weekly 
therapy may be more cytotoxic to cancer cells than comparable doses of 
monthly bolus schedules36.  
Drug interactions21  
 Doxorubicin is a potent radiosensitizing agent and radiation recall 
reactions are potentially dangerous.  
 Radiation may increase the risk of cardio toxicity of doxorubicin.  
 Interferon potentiates doxorubicin efficacy in follicular lymphoma. 
 Cyclosporine increases the toxicity of doxorubicin by inhibiting P-
glycoprotein 
 Vitamin  D 3  enhances the doxorubicin induced oxidative damage in 
breast cancer cells
 
 
 Pacletaxel modifies the  pharmacokinetic  profile  of  doxorubicin. 
CLINICAL TOXICITIES 18,22,23 
 Myelosuppression  is the most common toxicity  
 Stomatitis, mucositis, occurs in nearly 10% of patients.  
 Total or near total alopecia 21 occurs in nearly every patient. 
 Extravasations 
 Severe nausea and vomiting are common  
 Anorexia and diarrhoea may occur in less than 10% of patients.  
 Facial flushing, conjunctivitis, and lacrimation.  
 Cardiotoxicity:-18,22 Cardiac toxicity is a rare unusual but peculiar 
adverse effect observed with these agents. It leads to tachycardia, 
arrhythmias, dyspnoea, hypotension, pericardial effusion, and 
congestive heart failure which is poorly responsive to digitalis. 
 
 
                            CYCLOPHOSPHAMIDE  
         Cyclophosphamide is an alkylating agent and chemical derivative of 
mechlorethamine which was first synthesized in Germany in 1958 26.It is 
used as a single agent to treat burkitt´s lymphoma. As combination 
chemotherapy 17 in carcinoma  breast, ovary, lung and multiple myeloma. It 
is an immunosuppressant – used in nephritic syndrome, psoriasis. 
Metabolism  
 Causes Microsomal hydroxylation 
 It is hydrolysis to Phosphoramide mustard (active) and acrolein. 
 Excretion as inactive oxidation products. 
Mechanism of action 
 Produce DNA alkylation via the formation of reactive intermediates 
that attack nucleophilic sites. 
 Cell cycle non specific 20 
Dose schedule 
 Intravenous – 400 to 2000 mg/m2 
 Oral – 100 mg/m2 or 1 to 25 mg/kg/day in divided doses. 
                                      
 
Figure – 4  Metabolism of Cyclophosphamide18 
 
 
PHARMACOKINETICS  
Bioavailability:- Oral  >75 % ; Protein bound  > 60 % 
Primary elimination t ½:-Parent drug:-  3 – 10 hrs,    Aldophosphamide:- 
1.6 hrs, Phosphoramide mustard:-  8.7 hrs 
Toxicity 18,19 
       Myelosuppression is the major dose limiting toxicity of 
cyclophosphamide. It causes severe neutopenia than thrombocytopenia. 
Leucopenia develops after 8 – 14 days of therapy with recovery 1 or 2 
weeks later. Other common side effects are alopecia, pigmented finger nails, 
nausea, vomiting, pulmonary fibrosis, transient myopia, cataract, 
Haemorrhagic cystitis and SIADH. 
Teratogenesis – category D  in  FDA 
Cardiotoxicity 22,29,  
     Dose limiting cardiac toxicity occurs when using 7 fold increased normal 
dose,  ≥180 mg/kg for 4 or more days or  > 1.55 g/m2/day, mainly with 
transplantation  doses. Mechanisms underlying the toxicity are believed to 
be injury of both endothelial    cells and myocytes, and a picture of 
hemorrhagic myocardial necrosis can emerge. It causes low grade delayed 
cardiotoxicity which is not related with cumulative dose toxicity, more with 
patients older than 50 yrs of age. Maximum tolerated dose - 7000 mg/m2 
Precautions- Use   MESNA ( 2- Mercaptoethane sulfonate ) with high dose 
therapy. 
Drug interactions20  
 Increased cytotoxicity with radiation sensitizers and glutathione 
depletion. 
 Inhibit pseudo cholinesterase – risk of apnoea with succinyl choline. 
 Risk of cardiomyopathy when combine with anthracyclines. 
 Cimitidine enhances myelosuppression of cyclophosphamide.                                  
       
                              5 – FLUOROURACIL ( 5 – FU ) 
    5-Fluorouracil is an antimetabolite and structural analogue of DNA 
precursor of thymine 22. It is developed in 1957 by Heidelberger and 
Ansfield. It is used to treat carcinoma breast, gastrointestinal tract and many 
cancers. 
Metabolism  
          5-FU is a prodrug that enters cells and phosphorylated to series of 
metabolites. It is converted enzymatically to active nucleotide forms 
intracellularly. DPD (Dihydropyrimidine dehydrogenase) catalyzes the 
initial, rate limiting step in  5 FU catabolism. 
Mechanism of action 18,22 
        Fluorouridine   triphosphate incorporated   into RNA which interferes 
with RNA synthesis and its function. Thymidylate   synthase inhibition is 
mediated by fluorodeoxyuridylate (FdUMP) which   leads to thymidine 5´ 
monophosphate  and  thymidine 5´ triphosphate depletion. It also causes 
accumulation of  deoxyuridine monophosphate and deoxyuridine 
triphosphate. Incorporation of fluorodeoxyuridine triphosphate and 
deoxyuridine triphosphate  into DNA may  affect DNA stability. Genotoxic 
stress triggers programmed cell death pathways. 
         
Figure – 5   Mechanism of action of 5- Fluorouracil 
 
Pharmacokinetics  
 Half life  is 8 – 14 mts  after iv bolus infusion. 
 Nonlinear  pharmacokinetics due to saturable catabolism 
 Total body clearance decreases with increasing doses.  
Elimination  
 90% eliminated by metabolism; less than 10% excreted as unchanged 
in urine. 5 FU and its catabolites undergo biliary excretion. 
Drug interactions 
 Chronic administration of cimitidine –decrease 5-FU clearance. 
 Dipyridamole increases 5 –FU clearance . 
 Sequential Methotrexate (Mtx) use ĺ Mtx increases 5- FU toxicity 
and increases fluorouridine triphosphate (FUTP) incorporation into 
RNA; may antagonize DNA directed toxicity of  5 –FU. 
 Inhibitors of de novo pyrimydine synthesis increase 5 – FU anabolism 
to the ribonucleotide level and  5 FU – RNA incorporation. 
Toxicity  
 Gastrointestinal epithelial ulceration, Myelosuppression, skin rashes 
 Neurotoxicity – cerebellar ataxia, cognition dysfunction 
 Cardiac toxicity  
 It causes coronary spasm 22 & myocardial ischemia ( 1.6%) 29. 
 More common with high continuous infusion than iv bolus 
administration. Fluorouracil can cause acute ischemic 
syndromes ranging from angina to MI and this can occur in 
patients without CAD (approximately 1% of patients), although  
it  is  more  common  in patients with pre-existing disease (4% 
to 5%). 
 Vasospasm is believed to be the mechanism triggering 
ischemia, although thromboembolic events are also increased.   
               
             CHEMOTHERAPY INDUCED CARDIOTOXICITY 24 
    There are 2 types of drug induced cardiac toxicities commonly observed. 
Type  I  cardiotoxicity is more serious and causes permanent damage to the 
myocardium and type II which is usually reversible.     
               Type I cardiotoxicity found in Anthracyclines, type II 
cardiotoxicity found in traztuzumab 23. Anthracyclines induced 
cardiotoxicity is a cumulative dose dependent toxicity which is 
characterized by each administration constitutes additive or sequential 
damage to the heart.  
Figure – 6 Chemotherapy induced cardiotoxicity24     
 
  
ANTHRACYCLINE INDUCED CARDIO TOXICITY 23 - 30 
 Acute   and sub acute  cardiotoxicity 
 Delayed onset- irreversible  dilated cardiomyopathy 
 
ACUTE TOXICITY 25 
         Acute toxicity manifest during or soon after administration of the 
drug. It is generally minor and reversible and independent of anthracycline 
dose. Manifestations are asymptomatic ECG changes, Myocarditis, 
Pericarditis, transient heart failure may develop. Incidence - approximately 
11 % 
           ECG  changes 27,29  may be manifests are ST changes, Low  voltage  
QRS complex, Poor  R wave  progression, Prolongation  of  QT interval, 
Atrial  /  ventricular ectopics, T wave inversion, supra ventricular 
tachycardia, ventricular  arrhythmia. Conduction block is more common in 
paediatric age group. 
          An acute reversible reduction in ejection fraction is observed in some 
patients in the 24 hours after a single dose, and plasma troponin I, a cardiac 
enzyme released with myocardial damage, may increase in a minority of 
patients in the first few days following drug administration. 
SUB ACUTE TOXICITY 
           It develops days to weeks22 after completion of anthracycline therapy. 
Manifestations are:-Contractile dysfunction, Heart failure, Pericardial 
effusion, Arrhythmias – VT , SVT.  Insult to the myocardium  can  be  early  
detected  by  monitoring serum Troponin I  level 27 which may be used to 
predict the  future development of ventricular dysfunction. 
 
DELAYED TOXICITY 
        Chronic or delayed cardiotoxicity may manifests months or years after 
anthracycline therapy3,27. Commonest presentations:-Congestive heart 
failure, Dilated cardiomyopathy. Incidence – up to 20%.These produces 
progressive, irreversible myocardial damage which are fatal and results in 
cardiac death. Dilated cardiomyopathy is the most important long-term 
toxicity of doxorubicin 25. 
CUMULATIVE DOSE RELATED CARDIOTOXICITY 
      Cardiotoxicity is mainly due to dose administered during each cycle and 
on total cumulative dose28,. The risk of anthracycline cardiomyopathy 
depends on cumulative dose. A 5% risk is seen at 400 to 450 mg/m2 for 
doxorubicin 27, 900 mg/m2 for daunorubicin, 800 to 935 mg/m2 for 
epirubicin29, and 223 mg/m2 for idarubicin. 
  ECG changes found in 20 – 30 % of  patients. Arrhythmias like SVT,VT 
are developed in  0.5 – 0.7 % of the patients. Serious arrhythmias like atrial 
fibrillation, atrial flutters are not common in acute toxicity. This shows more 
doxorubicin induced cardiac failure will occur in near future who are now in 
asymptomatic.  
RISK FACTORS FOR CARDIOTOXICITY 26, 
 Cumulative dose - most significant risk factor 
 Age – elderly more than 60 yrs and  children up to 12 yrs 
 Sex -  females are more vulnerable 26 
 Length of  infusion – risk more with rapid bolus infusion 26 
 Patients with abnormal cardiac function 
 Mediastinal irradiation – prior or concomitant irradiation 30 
 Trisomy 21- higher risk of early clinical toxicity 32 
 Combination chemotherapy24,25 with high dose cyclophosphamide, 
bleomycin,vincristine, mitoxantrone , pacletaxel  etc. 
 Obesity – more drug need because of more surface area 
 Diseases – Hypertension, Diabetes mellitus, Coronary artery disease,  
 
PROPOSED MECHANISMS OF DOXORUBICIN  INDUCED 
CARDIAC TOXICITY 33,34 
 Oxidative stress 30 
 Mitochondrial dependant ROS 
 NOS dependant ROS 
 NADPH dependant ROS 
 Fe – Doxorubicin complex  
 Apoptosis 
 Intracellular calcium dysregulation 
 Changes in high energy phosphate pool 
 Endothelin-1upregulation 
 Extracellular matrix remodelling 
 RAS Activation 
Multiple mechanisms may involve in the formation anthracycline induced 
cardiomyopathy. Oxidative stress is the well accepted mechanism of the 
above all. 
 
 
MITOCHONDRIAL DEPENDANT ROS33 
    Mitochondria produce more than 90% of ATP needed for cardiomyocyte. 
Doxorubicin is a cationic drug which forms an irreversible complex with 
cardiolipin and the complex sequestered in the inner mitochondria. 
Doxorubicin alters cardiolipin protein interface within electron transport 
chain leads to more superoxide formation27,30. Protein responsible for 
carnitine transfer within mitochondria also disrupted, which leads to 
mitochondrial dysfunction. Pathological changes found are mitochondrial 
swelling, Myelin figure formation. 
            
                Figure – 7  Mechanism of  semiquinone formation 
        
           In an animal model of anthracycline induced cardiomyopathy showed 
that defect in long chain fatty acid oxidation, which coupled with excessive 
glucose metabolism within cardiac mitochondria. Development of 
congestive heart failure was mainly due to shift of aerobic metabolism into 
anaerobic one. 
      Sulaiman et al. found that doxorubicin disrupts mitochondrial gene 
expression and interfere with both nuclear and mitochondrial transcription 
regulation. Mn SOD is a free radical scavenger preserves mitochondrial 
function in doxorubicin cardiomyopathy. From this we can conclude that 
mitochondria play a vital role in the development of doxorubicin 
cardiomyopathy. So preservation of mitochondrial function will lead to 
better cardiac outcomes. 
NOS DEPENDANT ROS  
Nitric oxide synthase is an enzyme with three isoforms. These are 
 eNOS – Endothelial  
 iNOS – Inducible 
 nNOS – Neuronal 
NOS has two domain  
 Oxygenase  
 Reductase 
Doxorubicin binds to endothelial NOS reductase33 and causes superoxide 
formation. Doxorubicin semiquinone formation mediated by eNOS by 
reducing one electron is a calcium independent reaction. Nitric oxide 
generates superoxide by eNOS if doxorubicin concentration increases. So 
doxorubicin induced apoptosis is mediated by eNOS. Uncoupling of  eNOS 
leads to pressure induced heart failure. Role of  iNOS is not well defined. So 
eNOS has an important role in doxorubicin induced cardiomyopathy. 
 
NADPH dependant ROS38 
Doxorubicin combines with NADPH and forms oxygen free radicals. Acute 
cardiotoxicity is associated with SNP in the p22phox and Rac2 subunits. 
Chronic  toxicity is mediated by NADPH oxidase subunit NCF4. 
Figure-8 Doxorubicin induced apoptotic cardiac cell death        
 
Fe – Doxorubicin Complex28,34 
Doxorubicin has strong affinity for ferrous iron and forms iron –doxorubicin 
complex which interacts with negatively charged membrane and produce 
lipid peroxidation. Reduction of doxorubicin with the help of free iron leads 
to free radicals generation. Doxorubicinol a metabolite of doxorubicin 
interacts with thiol group of membrane protein leads to cell damage. 
Doxorubicinol forms complex with thiol group of cytoplasmic aconitase or 
iron regulatory protein (IRP) and enhances stability of transferring mRNA 
& prevents its translation. Further decrease in IRP increases free iron level 
which promotes free radical generation. These free radicals interfere with 
iron sequestration and causes doxorubicin cardiomyopathy. ROS interferes 
with the function of G protein through lipid peroxidation. ROS alter the 
tertiary structure of the proteins. ROS also induces calcium release in 
myocardium. 
APOPTOSIS30,32  
Reactive oxygen species induce the formation of free radicals which 
stimulate proapoptotic genes and induce apoptosis via both intrinsic and 
extrinsic pathways, causes death of cardiac myocytes. In an  apoptotic 
model, heat shock protein 1(HSP1) is activated by oxidative stress which 
promotes more HSP 25 protein production. By stabilizing p53 gene, HSP 25 
promotes proapoptotic pathway. HSP acts as molecular chaperones which 
stabilize the proteins involved in antiapoptotic pathway by inhibiting their 
dephophorylation, ubiquination and its degradation33. By these mechanisms 
HSP 10,27,60 and Bcl-2 are maintains mitochondrial functions. 
        Apoptosis is induced by the activation of caspase-3. Nitric oxide donor, 
s-nitrosyl-N-acetyl penicillamine (sNAP) produces antiapoptotic effects by 
suppressing caspase activity in cardiomyocyte with doxorubicin. 
Figure – 9 Role of Heat Shock Proteins in Cardiotoxicity                
 
 
INTRACELLULAR CALCIUM DYSREGULATION 
It may be due to ROS production. Reactive oxygen species and hydrogen 
peroxide alter normal calcium homeostasis through disruption of 
sarcoplasmic reticulum in cardiac myocytes. This is mainly mediated by 
decreased SERCA2 mRNA expression which leads to poor calcium 
handling. It may also due to ryanodine receptor activation. 
          
Figure – 10   Intracellular  calcium  dysregulation 
 
   Doxorubicin induces release of calcium from sarcoplasmic reticulum and 
opens the calcium channels. Doxorubicin increases L Type of calcium 
channel activity and inhibit sodium calcium exchanger channel in 
sarcoplasmic reticulum39. 
       Calpain,  a calcium dependent protease which is activated by calcium. 
Sarcoplasmic reticulum of cardiomyocyte contains more intracellular 
calcium. Oxidative stress induced by anthracyclines administration 
promotes calcium leakage, and activates calpain and cleavage of caspases-
12. Doxorubicin increases sensitivity of mitochondria to the intracellular 
calcium.  
MODIFICATIONS IN HIGH ENERGY PHOSPHATE POOL 
         Mitochondrial damage impairs the ability to generate adenosine tri 
phosphate (ATP). ATP depletion due to doxorubicin reduces the affinity of 
HSP 90 to ErbB2 which is a cardio protective protein. Because of ATP 
depletion, ErbB2 level also decreased. So HSP 90 unable to maintain its 
chaperone role. ATP depletion may be due to apoptosis and calcium 
dependent proteases which also consumes ATP. 
Tokarska – schlattner et al40. demonstrated in an animal model of 
doxorubicin may impair energy signaling through AMP activated protein 
kinase (AMPK) which is involved in the inhibition of oxidation of fatty acid 
and to reduce mitochondrial function. 
 
ENDOTHELIN-1 UPREGULATION33 
Endothelin-1 enhances cell survival signaling in cardiac cells. Its level is up 
regulated in patients with congestive heart failure who is previously treated 
with doxorubicin. Bien et al. demonstrated in an animal model that 
endothelin receptor antagonist, bosentan decrease anthracycline induced 
cardiomyopathy with preserved myocardial contraction. Endothelin receptor 
antagonist decreases TNF-α and BA↓ expression, lipid peroxidation. 
 
EXTRACELLULAR MATRIX REMODELING33 
       Anthracyclines inhibits matrix metalloproteinase 1(MMP-1)  and its 
transcription in tumor cells. But in heart it has opposite effect by increasing 
MMP-2 and MMP-9 levels. This leads to weakening of collgenous matrix 
and further progress to pathological remodeling which is depend on 
NADPH level. 
DOXORUBICIN INDUCED UPS ACTIVITY34 
      UPS is a proteolytic system which enhances the degradation and post 
translational modification of proteins. Anthracyclines activates UPS 
mediated proteolysis by  act on proteosomes. Doxorubicin potentiates 
MAPKS, P38 and  JNK which induces cardiomyocyte apoptosis by reduce 
the expression of antiapoptotic proteins like Bcl-2 and increases 
proapoptotic agents like Bax,caspase-3,caspase-9 etc. 
ACTIVATION OF  RENIN ANGIOTENSIN SYSTEM (RAS) & ACE 
ACTIVITY:-41-43 
        In  animal models of doxorubicin induced cardiotoxicity, an increased 
Angiotensin Converting Enzyme activity was noted. Okumura et al41.found 
that angiotensin converting enzyme (ACE) and chymase may involve in the 
production of doxorubicin induced cardiotoxicity in hamsters. Cardiac ACE 
activity was increased in doxorubicin induced cardiomyopathy hamsters. 
ACE inhibition significantly improved cardiac function and survival rate in 
hamsters. Lisinopril, treated hamsters improved mortality, cardiac 
remodeling and cardiac dysfunction in doxorubicin-induced 
cardiomyopathy suggest that ACE, plays a crucial role in the production of 
cardiomyopathy following the doxorubicin. 
            Toko et al42. found that AT1-mediated Ang II signaling pathway 
plays vital role in DOX-induced cardiac impairment. AT1 antagonist can be 
used to prevent DOX-induced cardiomyopathy. These results suggest that 
inhibition of the RAS in the heart may attenuate DOX-induced cardiac 
damage via a mechanism independent of blood pressure.Wen-na zong et 
al59. in their animal model of doxorubicin induced heart failure in rats 
explored that  the changes in plasma level of angiotensin-(1–7)[Ang-(1–7)] 
and myocardial expression of angiotensin II type 1/2 receptors (AT1R / 
AT2R) and Mas receptor.  
          Tokudome et al43.found that simultaneous administration of 
temocapril with doxorubicin in twenty male Sprague- Dawley rats protected 
against anthracyclines-induced cardiac damage. Myocardial tissue 
characterization was useful for the early detection of myocardial damage 
and the assessment of therapy. From these animal models data, RAS may 
also take part in anthracyclines cardiotoxicity. 
        Cardiac toxicity of anthracyclines may result from low levels of 
catalase in the heart combined with excessive mitochondria and myoglobin 
of the heart, which enhances the drug activation, as well as the sensitivity of 
cardiac glutathione peroxidase to free radicals attack. This destroys the 
activity of glutathione peroxides at the same time anthracycline 
administration stimulates cardiac hydrogen peroxide formation.  
     
Figure – 11   Doxorubicin induced Heart Failure 
 
      In contrast anthracyclines can be easily activated to its intermediates by 
hepatic enzymes; the liver has more active free radical defense systems and 
is able to actively efflux anthracyclines and its metabolites. It may result 
from doxorubicin itself or its major metabolite, doxorubicinol. The leading 
hypothesis for doxorubicin induced cardiotoxicity involves oxidative stress 
induced by free radicals formation. 
MONITORING  
      Treatment with anthracyclines may necessitate lifelong cardiac 
monitoring. General cardiac evaluation should be done to all the patients 
who are going to undergo doxorubicin therapy. Patients with cardiovascular 
risk factors need close and frequent monitor and keeping track on 
cumulative dose of doxorubicin44.  
Electrocardiogram28 
   Sinus tachycardia in previously normal heart rate is the earliest sign34  of   
cardiotoxicity. Failure to return baseline heart rate,  resting tachycardia, loss 
of respiratory variations to the heart rate are the important predictors of 
future cardiotoxicity. 
Echocardiogram44,46  
  It Provides  a  wide spectrum of  information on  morphological  and 
functional  view  of  the  heart & it is a non invasive method without  
Radiation exposure.  Left ventricular ejection fraction (LVEF) and 
Fractional Shortening (FS) are commonly monitored in systolic dysfunction. 
LVEF44:- 
           Baseline and serial measurement of  LVEF by echocardiogram is 
standard protocol in patients on anthracycline treatment44. It is the most 
commonly used non invasive parameter to detect cardiotoxicity earliest. 
                               LVEF =              EDV-ESV    X   100
                                                              EDV 
            EDV – End Diastolic Volume 
            ESV -  End Systolic Volume 
Normal LVEF is between 50% - 70%. LVEF is calculated by 2D 
echocardiogram and Modified Simpson’s formula. To decrease the inter-
observer variability, echo done by same physician for each patient at 
different time points. Mild – Ejection fraction less than 45%, Intermediate – 
EF between 45 – 50% , severe toxicity EF < 45%.Stop doxorubicin therapy 
if  LVEF decrease 15% from baseline value. 
 
FRACTIONAL SHORTENING36,46,:- 
Calcuted from the following formula  
                   FS =         LVIDd – LVIDs      X 100     
                                             LVIDd 
LVIDd  - Left ventricular internal diameter in diastole 
LVIDs  - Left ventricular internal diameter in systole 
   Both LVEF and FS decrease in left ventricular systolic 
dysfunction44.Reduction in LVEF and FS precedes development of CHF, if 
we stop further infusion of doxorubicin we can decrease further progression 
of heart failure. 
         All patients should have a baseline measure of LVEF. For 
doxorubicin, poor-risk patients should have a repeat study at 200 mg/m2, 
and all patients should have a follow-up study at 300 to 400 mg/m2 and 
every 50 to 100 mg/m2 thereafter28.  
 
Radionuclide ventrculography46 
      Well established method to determine LVEF35. It  can be used to 
determine regional wall motion and diastolic function by serial monitoring. 
It is an invasive procedure and exposure to radiation is limits its use 
routinely. 
 
Cardiac biomarkers46 
        Troponin I ,T and Brain Natriuretic Peptide (BNP) are commonly used 
serological markers to detect early myocardial damage. B-type natriuretic 
peptide levels and troponin I levels, appear to hold the greatest promise as 
these are simple plasma markers and may correlate with subclinical left 
ventricular diastolic dysfunction.  
 
 Troponins28,47  
      Quantification of cardiac contractile   proteins such as   Troponin  is a 
highly sensitive  method of detecting myocardial cell injury and 
anthracyclines  induced  cardiotoxicity as well. Troponin I levels may be 
elevate in doxorubicin treated patients before deterioration in LVEF. 
Elevation of  troponin I  level after exposure to anthracyclines, an indicator 
of early cell death which may be beginning of ongoing process. Elevation of 
troponin I  which correlate with subclinical LV Dysfunction. 
Natriuretic peptide27  
        These are released from the  atria (ANP), left ventricle (BNP) in 
response to circulating volume and intra cardiac pressures. BNP level 
correlates  more with diastolic dysfunction than systolic dysfunction. Both 
troponin and BNP are highly specific and sensitive tool for early detection 
of myocardial defect. 
MRI:-Valuable tool to assess myocardial function and damage 
 
Computed tomography:-High radiation exposure, Low temporal resolution 
 
Scintigraphy46:-Sensitive method to detect myocytes damage. Monoclonal 
antibody to cardiac myosin is tagged with I 131. 
 
 Endo Myocardial Biopsy (EMB)28,30 
         An invasive procedure,  biopsy taken from endocardium of right 
ventricle of the heart. Gold standard investigation for anthracycline 
cardiomyopathy and provides histological evidence of cardiotoxicity. Total 
doses of doxorubicin as low as 250 mg/m2 can cause pathological changes 
in the myocardium, as demonstrated by subendocardial biopsies. 
Histological changes may be found are mitochondrial swelling, Myofibrillar 
drop out, stellate scars, Vesicular dilatation, Adria cells, Myocytes 
hypertrophy, Myocytes degeneration and Loss of cross striations. 
Disadvantages are High cost, Need experts to do biopsy and to interpret its 
histology, only small sample of myocardium is tested. 
 
STRATEGIES TO REDUCE DOXORUBICIN CARDIOTOXICITY   
     With awareness of the cardiac risk, anthracycline cardiotoxicity may be 
avoided by recognizing risk factors, early detection, limiting total 
cumulative dose, and more recently, using cardio protective agents or 
modified infusion drug regimens. 
The prevention of doxorubicin induced cardiotoxicity depends on three 
approaches:  
 Regular monitoring of cardiac function 28 
 Using  analogues  of anthracycline with less cardiotoxicity 
 Modified administration of doxorubicin30.  
Doxorubicin toxicity can be minimized by: 
 Changes in doxorubicin administration to continuous infusion. 
 Minimizing  the total cumulative dose to<400 mg/m2 
 Using liposomal - encapsulated  doxorubicin28. 
 Using dexrazoxane to decrease the free iron formation. But it should 
be used only after exposure of doxorubicin dose of 300mg/m2 
because of the possibility of its ability to diminish the effect of 
anticancer agents.  
 Using antioxidant to reduce the production of ROS with N-acetyl 
cysteine, coenzyme Q10. 
 Treatment of early cardiac events needed, to minimize the evolution 
of doxorubicin-induced cardiotoxicity.  
 ACE Inhibitors and β-blockers are routinely used to treat the late 
cardiac dysfunctions. ACE Inhibitors have been used to slow the 
progression of left ventricular dysfunction in many clinical conditions 
also in patients undergoing doxorubicin therapy. Hence early 
administration with enalapril seems to prevent the progression of late 
cardiotoxicity.  
 
Figure – 12  Strategies to  Reduce  Doxorubicin Induced 
Cardiotoxicity 
 
 
 
RISK FACTORS SCREENING AND PREVENTION OF CARDIAC 
EVENTS 
             All patients should be screened for preexisting cardiac risk factors 
like hypertension, diabetes, obesity and smoking before commencing 
therapy with doxorubicin. ACE inhibitors with or without beta blocker 
administration during the early course of the toxicity shows increased 
efficacy in the prevention of  delayed cardiac events. Pretreatment with 
these agents can prevent the fall in ejection fraction seen with patient’s 
undergone high-dose chemotherapy. 
 
Dose limitation  
                 The risk of cardiotoxicity can be reduced by keeping the total 
cumulative dose of doxorubicin well below550mg/m2. It is recommended 
that the lifetime dose should be <450-550 mg/m2 for doxorubicin. It is better 
to limit the doxorubicin cumulative dose less than 350 mg/m2 in patients 
with cardiovascular risk factors which decrease the need of careful 
monitoring.  
 
Schedule Modification32  
        Delayed cardiotoxicity is mainly related to peak doxorubicin 
concentration. Antineoplastic activity is more related to total drug exposure 
( Conc x AUC). A prolonged infusion of doxorubicin has been less 
cardiotoxic than bolus injections. An important   strategy to be followed to 
reduce the risk of cardiotoxicity is infusion over several hours. Weekly 
regimen schedule allowed more drug up to 200 mg/m2 doxorubicin which 
may be tolerated by the individuals compared to 21 day routine cycle and 
also improve biopsy score. Continuous infusion (24-96 hrs) are safe by 
minimize the plasma drug concentration while maintaining antitumor effect 
which is confirmed by endomyocardial biopsy44. These measures reduce the 
cardiotoxicity of anthracyclines but did not prevent it. Rapid bolus infusion 
saline increased risk of extravasations / tissue necrosis. Using central line 
for prolonged >24 hrs infusion, would reduce the risk of extravasations. 
Drawback of central line infusion 
        Increase the risk of infections, more time consuming to set up and ﬂush 
the line weekly, line position checked by chest x ray, more than 96 hrs 
continuous infusions may leads to more chance of hand foot syndrome and 
mucositis, need of portal infusion pump and indwelling catheters.  
ALTERNATIVE STRATEGIES  
Liposomal Anthracyclines28,44 
        Liposomal formulations have been introduced to enhance the 
therapeutic index of free doxorubicin by encapsulation of doxorubicin 
within a macromolecular vector, such as a liposome. It permit more specific 
organ targeting of doxorubicin, less volume of distribution, less  diffusion 
and less toxicity for healthy tissues . 
Formulations of liposomal anthracyclines18  
 Pegylated  liposomal doxorubicin 
 Non pegylated  liposomal doxorubicin  
 Other unique delivery systems :- Starch microspheres, Albumic 
microspheres, Lipeodal Doxorubicin 
FDA recently approved liposomal formulations of doxorubicin for Kaposi 
sarcoma, carcinoma ovary, breast and Multiple Myeloma. These 
formulations have same efficacy with minimal cardiac toxicity when 
compared with free doxorubicin. Less chance of developing cardiotoxicity 
with pegylated liposomal doxorubicin than with normal one in all subgroups 
analyzed ( age>65 yrs, prior anthracyclines therapy). However they may 
cause hand–foot syndrome and Stomatitis. 
        Non-pegylated liposomal doxorubicin is less cardiotoxic than 
conventional doxorubicin. It has comparable antitumor activity with less 
diarrhea and nausea/vomiting, neutopenia. Findings from a meta-analysis 
showed a lower rate of clinical and subclinical heart failure with 
nonpegylated liposomal doxorubicin.  
            Hence Liposomal doxorubicin should be used in patients with 
metastatic breast cancer who are at high risk. Nonpegylated liposomal 
doxorubicin is more efficacious and less cardiotoxic over free doxorubicin 
for patients treated adjuvant with anthracyclines iron-chelating agents. 
 
Anthracycline analogues27 
       Analogue development holds the promise of good antitumor activity 
with less cardiotoxicity. Epirubicin produce heart failure only in 10% of 
breast cancer patients took cumulative dose of more than 600mg/m2.  
Idarubicin 
      The dose of idarubicin is 12 mg/m2/day for 3 days by intravenous 
injection. Slow injection over 10-15 minutes is followed to avoid 
extravasations. It has less cardiotoxicity than doxorubicin. 
Daunorubicin 
          Daunorubicin (rubidomycin, daunomycin) is infused intravenously. 
The dose is 25-45 mg/m2/day for 3 days. Total doses of >1000 mg/m2 are 
associated with risk of cardiotoxicity. 
Epirubicin  
          It is indicated in adjunctive therapy for treatment of breast cancer. It is 
administered in doses of 100-120 mg/m2 intravenously every 3-4 weeks. 
Total doses >900 mg/m2 sharply increase the risk of cardiotoxicity. Its 
toxicity profile is the same as that of doxorubicin. 
Valrubicin  
         Valrubicin is a semi-synthetic analog of doxorubicin, used exclusively 
for intravesicular treatment of bladder cancer. 800mg are instilled into the 
bladder once a week for 6 weeks. Less than 10% of instilled drug is 
absorbed systemically.  
REGIMENS WITHOUT ANTHRACYCLINES44:- 
       Another strategy to reduce cardiotoxicity is simply not to use 
doxorubicin. Although taxanes also have a potential cardiovascular risk, in a 
comparative study found that treatment with docetaxel conferred no 
apparent cardiotoxicity benefit than doxorubicin. Thus, the choice of agent 
than doxorubicin should be balanced against reduction in antitumor efficacy 
and against the overall toxicity profile of the two agents.  Cardiac events 
occur during doxorubicin schedule or in the first year after its completion is 
often manifesting as arrhythmias, such as atrial fibrillation or pericarditis. 
These should be treated according to guidelines, which may heart rate or 
rhythm modifying drugs and antithrombotic agents. Patients with 
symptomatic CHF should receive ACE inhibitors and beta blockers. 
Blocking agents44 
          Differences in the biochemical mechanisms of antitumor and 
cardiotoxic activity provide a potential avenue of selectively inhibiting or 
preventing the adverse effect. 
Targets for the approach 
 Agents that  prevent free radicals generation  
 Salvage free radicals.                                    
                                     FREE RADICALS50 
Oxidative Free radicals are constantly formed in the human system and has 
been implicated in several human diseases. These free radicals are 
scavenged or removed by enzymatic and non enzymatic antioxidant defense 
mechanism. When these defense mechanisms are inadequate, oxidative 
stress can damage proteins, carbohydrates, lipids and nucleic acids. 
A free radical contains one or more unpaired electrons in their orbitals. 
When two radicals meet, they can combine their unpaired electrons and join 
to form a covalent bond 
                                      AO + AO ----------- A ---A 
Types of free radicals 
Hydroxyl radicals (*OH) 
It is one of the most reactive free radical, important role in tissue damage by 
radiation.*OH radical causes DNA fragmentation and extensive alterations 
in the purine and pyrimidine bases. Hydroxyl radicals (*OH) are also known 
to induce lipid peroxidation of fatty acid side chains of membrane 
phospholipids. Accumulation of lipid peroxides in a biological membrane 
disrupts its integrity and function.  
Superoxide radicals 
                        O
 2 + e 
-
 ---------- O2 . - 
Superoxide radicals (O2 . -)  is an oxygen molecule deficient of one electron, 
involved  in  the regulation of fibroblast proliferation, vasodilatation and 
phagocytosis.H2O2 is not a free radical but is a powerful oxidizing agent and 
is removed by the enzymes catalase and glutathione peroxidase. 
Nitric oxide  
NO has one unpaired electron and can be regarded as free radical. 
Combination of NO with superoxide radicals results in the formation of 
peroxynitenite (OONO) which is highly toxic. 
Transition metal ions and free radicals 
Iron and copper ions are excellent promoters of free radical formation. 
These can convert H2O2 in to highly reactive  *OH , leads to accumulation 
of cytotoxic end products of  lipid peroxides. 
Antioxidant defensive mechanisms 
Antioxidant or free radical scavenger is a substance at low concentrations 
can prevent or delay the oxidation of an oxidizable substrate. 
Major intracellular  Antioxidants50 
SOD, Catalase, Glutathione peroxidase, α Tocopherol, Ascorbic acid 
Major Extracellular Antioxidants 
Uric acid, Bilirubin, Ceruloplasmin, Albumin, α Tocopherol, Ascorbic acid 
 
OXIDATIVE STRESS AND DISEASE50 
Disease involving several organs / systems 
Rheumatoid arthritis, Myocardial infarction, Malignancy and Aging  
Disease involving specific organs / systems 
Nervous system:-  parkinsonism, Alzheimer’s disease; Renal system:- 
heavy metal, aminoglycoside &  NSAIDs toxicity; Respiratory system:- 
emphysema, oxygen toxicity; Endocrine :- diabetes mellitus; Drug 
toxicity:- Anthracyclines, halothane, chloroform, Lead poisoning, 
Antimalarials – Haemolysis. 
ANTIOXIDANTS OF NATURAL ORIGIN 
Superoxide dismutase (SOD)  
      The enzyme superoxide dismutase (SOD), found in all cells and  is 
necessary for scavenging the  Superoxide radical and prevent its 
accumulation and production of oxidative stress to the living system. SOD 
catalyzes a dismutation reaction, where by one  O2 . – is oxidized to  O2 and 
the other reduced to H2O2. 
                      
O2 + O2 . – + 2H ----------- H2O2 + O2 
It protect against ischemic or reperfusion injury seen after MI, cerebral 
stroke or organ transplants. The large inflow of oxygen during reperfusion 
results in generation of  O2 . –  and  H2O2 which can be scavenged  by SOD. 
Alpha Tocopherol 
   Severe neurological damage, hemolytic syndrome, atherosclerosis, 
retrolental fibroplasias. 
Ascorbic acid  
Vitamin c is an essential component of human diet and functions as a 
cofactor of several hydrolyze enzymes. Useful in atherosclerosis and 
cancers. 
Physiological  antioxidants50 
     Lactoferrin – iron binding protein, Nicotanamide, Glutathione – organ 
transplantation, cystic fibrosis, AIDS- p.carnii pneumonia, Acetylcysteine – 
paracetamol poisoning, Beta carotene – anti cancer effect, Melatonin.  
Synthetic antioxidants:- Allopurinol , Desferrioxamine,  Probucol. 
Drugs with additional antioxidant  property50 
ACE Inhibitors, Calcium channel blockers, NSAIDs, Selegiline.  
 
Free radical scavengers50 
 ↑itamin E (α Tocopherol),N-Acetylcysteine, Coenzyme Q10, 
Phrenylamine, Dexrazoxane and ACE Inhibitors. 
 
 
                                          DEXRAZOXANE8,49  
        Dexrazoxane is a prodrug of bisdioxopiperazine derivative. It is an  
iron chelating agent. Highly effective in reducing doxorubicin induced 
cardiotoxicity and extravasations injury. It is the only FDA approved drug 
to prevent doxorubicin induced cardiotoxicity. Intracellularly it is 
hydrolyzed to form bidentate chelator. Structurally it is similar to EDTA 
also a strong inhibitor of topoisomerase II enzyme. It quickly binds to intra 
cellular iron and strips Fe 2+ from iron – doxorubicin complex by which it 
decrease the generation of free radicals8. Although its benefits against late 
cardiotoxicity not proved, but it is known to decrease the acute 
cardiotoxicity of doxorubicin. Dexrazoxane also have decrease antitumor 
response rate to the anthracycline treatment. Route of administration – 
intravenous. Biphasic elimination – distribution T ½  - 0.8 hrs, elimination T 
½  -9 hrs. Though dexrazoxane may be useful to reduce cardiotoxicity; its use 
should be weighed against the risk of a lower response rate49 and the 
additional costs of treatment. 
 
    
 
                     RENIN AND ANGIOTENSIN SYSTEM (RAS) 
    Pathophysiology of heart failure, hypertension, myocardial infarction, 
diabetic nephropathy and chemotherapy induced cardiotoxicity are mediated 
by the renin–angiotensin system (RAS). There are two forms of Angiotensin 
identified, Angiotensin I [AngI]) & Angiotensin II [AngII]) derived by 
cleavage of AngI by an enzyme termed Angiotensin-converting enzyme 
(ACE). The   AngII is to be the more active form53. 
Components of the Renin–Angiotensin System52 
        AngI derived from the angiotensinogen with the help of renin. ACE 
convert AngI to produce the AngII which in turn act on AT1 and AT2 
receptors. An alternative ACE independent pathway also involved in AngII 
synthesis. Biologically active Angiotensin  peptides (AngIII, AngIV, 
Ang[1–7]), Angiotensin binding receptors AT1, AT2, AT4, Mas are involve 
in cellular  hypertrophy, fibrosis, inflammation and  apoptosis. 
Short -loop negative feedback52 :-Increased renin stimulates the formation 
of AngII, which  in turn stimulates AT1 receptors on juxtaglomerular cells to 
inhibit renin release.  
Long-loop negative feedback52:- an AngII-induced increase in blood 
pressure inhibits renin release. ACE inhibitors, Angiotensin receptor 
blockers (ARBs), and renin inhibitors interrupt both the short- and long-loop 
negative feedback mechanisms and therefore increase renin release.     
  Angiotensin converting enzyme:-  
   Angiotensin Converting Enzyme (kininase II, Dipeptidyl 
carboxypeptidase)is an ectoenzyme which  is identical to kininase II, the 
enzyme that inactivates bradykinin and other potent vasodilator peptides.  
Angiotensin-Converting Enzyme 2 
     ACE2 cleaves one amino acid from the carboxyl terminal to convert 
AngI to Ang(1–9) and AngII to Ang(1–7). It  act as a counter-regulatory 
mechanism to oppose the effects of ACE. ACE2 regulates the levels of 
AngII and limits its effects by converting it to Ang(1–7), which binds to 
Mas receptors and elicits vasodilator and anti-proliferative responses.ACE2 
is not inhibited by the standard ACE inhibitors and has no effect on 
bradykinin.  
Angiotensin(1-7)54 :- Angiotensin(1-7) is formed by many  pathways. 
Ang(1–7) opposes many of the effects of AngII: causes vasodilatation, NO 
production, potentiates the vasodilator effects of bradykinin, has  anti-
angiogenic, anti-proliferative & cardio protective  in  cardiac ischemia and 
heart failure. These effects are modulated through Mas receptor.  
Figure – 13 Renin Angiotensin System and its Physiological action on 
cardiovascular system52 
 
 
 
 
 
Angiotensin Receptors53 
AT1 receptors stimulate the membrane-bound NADH/NADPH oxidase 
which generates reactive oxygen species (ROS). ROS may contribute to 
biochemical effects and physiological effects. The  AT2 receptors may 
counterbalance many of the effects of the AT1 receptors. 
Functions and Effects of the Renin–Angiotensin System53,54                                           
The main effects of AngII on the cardiovascular system include: fast   
pressor response, slow pressor response, Vascular and Cardiac hypertrophy 
and remodeling. This rapid pressor response to AngII is due to rise in total 
peripheral resistance. AngII stimulates the synthesis of endothelin-1 and 
superoxide anion, which may contribute to the slow pressor response. AngII 
stimulates the cardiovascular remodeling, vascular and cardiac cells 
hypertrophy and excessive synthesis and deposition of collagen by cardiac 
fibroblasts. 
Cardiovascular Hypertrophy and Remodeling53 
    These effects of AngII are mediated by acting directly on cells to induce 
the expression of specific proto-oncogenes (c-fos, c-jun, c-myc, and egr-1) 
that alter the expression of growth factors such as basic FGF, PDGF, and 
TGF- β. In addition, changes in cardiac preload (volume expansion owing to 
Na+ retention) and afterload (increased arterial blood pressure) probably 
contribute to cardiac hypertrophy and remodeling.  
Figure – 14  Angiotensin II mediated  Pathophysiology on Heart52 
 
INHIBITORS OF THE RENIN–ANGIOTENSIN SYSTEM54 
Three types of inhibitors of RAS system are utilized therapeutically  
 ACE inhibitors (ACEIs)  
 Angiotensin  receptor blockers (ARBs)  
 Direct  renin inhibitors (DRIs) 
          ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 
History52 
In the 1960s, Ferreira and colleagues found that of pit viper venoms have  
factors that intensify vasodilator responses to bradykinin. These bradykinin-
stimulating factors are a family of peptides that inhibit kininase II, an 
enzyme that inactivates bradykinin. Erdös and coworkers found that 
kininase II and ACE are the same enzyme, which catalyzes both the 
synthesis of AngII and the destruction of bradykinin. It decreased blood 
pressure in many patients with hypertension and beneficial effects in 
patients with heart failure. 
 
CLASSIFICATION OF ACE INHIBITORS53  
Sulfhydryl- ACE inhibitor – Captopril 
Phosphorus - ACE inhibitors – Fosinopril 
Dicarboxyl- ACE inhibitors - Enalapril, Ramipril, Lisinopril, Quinapril, 
Benazepril, Perindopril   Moexipril, Trandolapril.    
                    
 
Figure – 15   Agents interferes with RAS System53 
 
  Captopril and lisinopril are active drugs. All other are prodrugs. These 
prodrugs are inactive until converted to their corresponding di-acids. Kidney 
is the primary root of excretion in most of the ACE inhibitors. Patients with 
poor renal function diminish the plasma clearance of these agents and doses 
should be decreased in patients with renal impairment55. Initial dosages of 
all ACE inhibitors should be reduced in patients with high plasma levels of 
renin (e.g., patients with heart failure and salt-depleted patients). All ACE 
inhibitors have similar therapeutic indications, adverse-effect profiles.  
 
 
ENALAPRIL 
         Figure – 16  Chemical structure of Enalapril 
                      
 
              Enalapril is an orally active ACE Inhibitor without Sulfhydryl 
group53 has longer duration of action than Captopril. Enalapril maleate is a 
prodrug which is hydrolyzed in the liver to enalaprilat. Enalaprilat is a 
powerful inhibitor of ACE. Enalapril is absorbed rapidly orally with an oral 
bioavailability of ~60%. Although peak plasma concentrations of enalapril 
occur within an hour, enalaprilat peak concentrations achieves only after 3-4 
hrs. Enalapril has a half life of t1/2 ~1.3 hours, but enalaprilat plasma t1/2 of 
~11 hours because of its tight binding to ACE. Enalapril is eliminated by the 
kidneys. The dosage of enalapril ranges from 2.5-40 mg daily (single or 
divided dose), with 2.5 and 5 mg daily being appropriate for the initiation of 
therapy for heart failure and hypertension, respectively53. 
Pharmacology  
             Enalapril is inactive until de-esterifies into enalaprilat, a specific 
competitive inhibitor of  ACE. ACE Inhibitors reduces plasma Angiotensin 
II levels and as a result of loss of feedback inhibition, plasma rennin activity 
increases. Plasma aldosterone may be reduced, which can increases plasma 
potassium. ACE inhibition may increase bradykinin level, a potent 
vasodilator and stimulate prostaglandins, EDRF, NO. Enalapril in single 
dose of 2.5 – 20 mg blunts the BP response to injected Angiotensin I  for 
more than 4 hrs while plasma ACE activity decreased up to 24 hrs. Plasma  
renin activity increases while that of Angiotensin II and aldosterone 
decrease. The BP fall is due to peripheral vasodilatation without reflex 
tachycardia. Bradykinin   is degraded by  peptidyl  dipeptidase also known 
as ACE, some of the effects of ACE inhibition  may be due to elevated 
bradykinin.  
Pharmacokinetics 
        After  oral  intake of 10 mg  of  enalapril  reaches  peak  level  in 1 hr 
but its active  form  enalaprilat  peaks  at  4 hrs52. Oral absorption ≥ 60%, 
absorption is not affected by food. Bioavailability is 40%. Urinary excretion 
is about 70%.    Plasma half life of Enalapril is short, but for Enalaprilat is 
35 hrs. Plasma binding protein (Enalaprilat) is 60%. 
Metabolism  
In vivo enalapril rapidly  converted  into  enalaprilat. There  is  no  evidence  
of  further  metabolism  because  94%  of  orally  administered  enalapril is  
recovered  as  either  enalaprilat  or  its  di- acid. 
THERAPEUTIC USES OF  ENALAPRIL52-55 
Enalapril that interfere with the RAS play a prominent role in the treatment 
of cardiovascular disease. 
 Hypertension- ACE inhibitors monotherapy decrease the blood 
pressure in ~50% of patients with moderate hypertension. 90% of 
patients with mild to moderate hypertension will be controlled by the 
combination of an ACE inhibitor and either a Ca2+ channel blocker, a 
β adrenergic receptor blocker, or a diuretic. 
 Acute Myocardial Infarction - The beneficial effects of ACE 
inhibitors in acute myocardial infarction are particularly large in 
hypertensive and diabetic patients. In high-risk patients (e.g., large 
infarct, systolic ventricular dysfunction), ACE inhibition should be 
continued for long term. 
 Diabetes Mellitus and Renal Failure - Reno protection in type 1  
diabetes, as defined by changes in albumin excretion, and are 
independent of blood pressure reduction. In addition, ACE inhibitors 
may decrease retinopathy progression in type 1 diabetics and 
minimize the progression of renal insufficiency.  
 Renal protection - By lowering arterial blood pressure and by 
dilating renal efferent arterioles, ACE inhibitors reduce this 
glomerular injury. 
 Scleroderma Renal Crisis - improves survival of patients with 
scleroderma renal crisis.  
 Left Ventricular Systolic Dysfunction and CHF52 
ACE inhibitors should be started in all asymptomatic & symptomatic 
patients with impaired left ventricular systolic function. The more severe the 
ventricular dysfunction,  the greater the benefit from ACE inhibition. 
 Prevents or delays the progression of heart failure 
 Decreases the incidence of sudden death and myocardial infarction,  
 Decreases hospital admission  
 Improves quality of life.  
Inhibition of ACE commonly  
 Reduces  afterload  and systolic wall stress  
 Increase both cardiac index and cardiac output 
 Improve indices of stroke volume.  
     In systolic dysfunction, AngII decreases arterial compliance, and this is 
reversed by ACE inhibition. Heart rate & Systemic blood pressure falls, 
Reno vascular resistance falls sharply, and renal blood flow increases. 
Natriuresis occurs as a result of the improved renal hemodynamic, the 
reduced stimulus to the secretion of aldosterone by AngII, and the 
diminished direct effects of AngII on the kidney. The excess volume of 
body fluids contracts, which reduces venous return to the right side of the 
heart. A further reduction results from venodilation and an increased 
capacity of the venous bed. 
         The response to ACE inhibitors also involves reductions of pulmonary 
arterial pressure, pulmonary capillary wedge pressure, and left atrial and left 
ventricular filling volumes and pressures. Consequently, preload and 
diastolic wall stress are diminished. The better hemodynamic performance 
results in increased exercise tolerance52 and suppression of the sympathetic 
nervous system. Cerebral and coronary blood flows usually are well 
maintained, even when systemic blood pressure is reduced. 
        In heart failure, ACE inhibitors reduce ventricular dilation and tend to 
restore the heart to its normal elliptical shape. ACE inhibitors may reverse 
ventricular remodeling via changes in preload/afterload, by preventing the 
growth effects of AngII on myocytes, and by attenuating cardiac fibrosis 
induced by AngII and  aldosterone55. 
ACE Inhibitors and Survival in CHF52 
      Independent of etiology ACE inhibitors improves survival in patients 
with CHF due to systolic dysfunction. CONSENSUS Trial demonstrated a 
40% mortality reduction after 6 months of enalapril therapy in severe CHF, 
while others have shown that enalapril also improves survival in patients 
with mild-to-moderate CHF. ACE inhibitors slow the development of 
symptomatic CHF in asymptomatic LV dysfunction. 
ADVERSE EFFECTS OF ACE INHIBITORS 
      In general, ACE inhibitors are generally well tolerated group of drugs. 
They   rarely produce metabolic side effects on long-term therapy. Improves 
insulin sensitivity and reduce the cholesterol and lipoprotein (a) levels in 
proteinuric patients. 
Hypotension- In patients with elevated PRA fall in blood pressure can 
occur following the first dose of an ACE inhibitor.  
Cough - ACE inhibitors produce dry cough in 5-20% of patients54 due to 
the accumulation of bradykinin, substance P, prostaglandins in the lungs. 
Hyperkalemia53 - ACE inhibitors may produce hyperkalemia in patients 
with renal failure, diabetic patients or in patients taking K+-sparing diuretics, 
K+ supplements, β adrenergic blockers, NSAIDs. However K+ retention is 
rarely encountered in patients with normal renal function. 
Acute Renal Failure - ACE Inhibition may precipitate  acute renal failure 
in patients with history of bilateral renal artery stenosis, renal artery stenosis 
of a single remaining kidney, congestive heart failure, or hypovolemic state 
due to   diarrhoea  or diuretics. 
Teratogenic Potential55 - ACE inhibitors should be discontinued as soon as 
pregnancy is confirmed. Pregnant women exposed  to  ACEI  associated  
with  Pulmonary  hypoplasia, IUGR, Premature  labour,  Bony  
malformations and Limb  contractures.   
Angioedema - ACE inhibitors may induce a rapid swelling in the nose, 
larynx, lips, throat, mouth, glottis, and tongue in less than 0.5% of patients. 
Other Side  Effects 
 Dysgeusia (an alteration in or loss of taste), Skin rash 
 Neutopenia (symptoms include sore throat and fever)54  
 Glycosuria, Hepatotoxicity.  
CONTRAINDICATIONS  
 Known  hypersensitivity  to ACE  inhibitors 
 Angioneurotic edema relating  to  previous ACEI  therapy 
 Bilateral  renal  artery  stenosis55 
 Stenosis  to  a  single  solitary  kidney53 
 Aortic  stenosis  or  outflow  tract  obstruction 
DRUG INTERACTIONS 
 Bioavailability of ACE inhibitors decreased by antacids.  
 ACE inhibitor–induced cough is worsened by capsaicin. 
 NSAIDs reduce the antihypertensive response to ACE inhibitors by  
blocking  PG  synthesis 
 NSAIDs and  ACEI  combination precipitates  nephrotoxicity. 
 K+-sparing diuretics & K+ supplements may aggravate ACE 
inhibitor–induced hyperkalemia54.  
 ACE inhibitors increase plasma digoxin and lithium concentrations 
 ACE inhibitors increase hypersensitivity reactions to allopurinol. 
 Diuretics accentuates hypotensive action of  ACEI53. 
ACE INHIBITORS AND OXIDATIVE STRESS51,60 
       ACE inhibitor like enalapril has important role in prevention of 
oxidative stress in vascular smooth muscles. Cells of smooth muscle, 
endothelium, and fibroblasts are using NADH or NADPH as a substrate for 
the formation of superoxide anion in response to Angiotensin II60 activation. 
Therefore, superoxide production may be increased in conditions where 
renin angiotensin system is activated. Atherosclerosis is one of the risk 
factor for heart disease in which ACE and vascular NAD(P)H oxidase 
activity is increased. Progression of atherosclerosis mediated cardiac events 
mainly due to NAD(P)H oxidase activation and increased level of 
superoxide within the vascular wall. Combination of Superoxide with NO is 
much faster than the superoxide dismutation reaction. Peroxynitrite is 
produced by this reaction shunting NO from its typical targets like 
vasodilatation and platelet inhibition. Thus, reduction of NO bioactivity and 
promotion of oxidative stress in the blood vessels are mainly due to the dual 
effect of vascular super oxides. 
        Superoxide has an important role in the development of cardio vascular 
disease because of NADPH oxidase overactivity61. Hydrogen peroxide 
(H2O2) is produced by superoxide dismutase associated with lipid oxidation 
with the help of transition metals. Apoptosis & necrosis in cardiovascular 
cells are induced by  H2O2 over activity.  
        Proliferation of smooth muscle cell is stimulated by  H2O2. H2O2 also 
inhibits endothelial cells proliferation. H2O2 increases the expression of 
endothelin-1 and activates of proapoptotic pathway in endothelial cells. 
Smooth muscle hypertrophy and hypertension are mainly mediated by 
NAD(P)H oxidase activation in response to Angiotensin II . 
 
 
ACE Inhibition as an Antioxidant Strategy  
        Chopra et al51.described about antioxidant effects ACE inhibitors in his 
experimental model. He quoted that free radical and oxidant scavenging 
effects are depends on Sulfhydryl group. Sulfhydryl - and nonsulfhydryl 
containing ACE inhibitors like enalapril inhibits the lipid peroxidation. 
            Richard et al58.found that expression of bradykinin receptor & ACE 
inhibition on oxidative stress during anthracycline-induced cardiomyopathy 
in animal models.              
               ACE inhibitors have an antioxidant property which targets 
oxidative stress at its source level confirmed by the link between vascular 
NAD(P)H oxidase activity and ACE action. Enalapril inhibits NAD(P)H 
oxidase stimulation, by which it prevents renin-angiotensin system mediated 
superoxide flux. In hypertension and coronary artery disease superoxide 
reacts with NO, which further inhibit the NAD(P)H oxidase activity. NO 
bioactivity is improved by ACE Inhibition which in turn reduces the 
superoxide levels in the vascular wall. ACE inhibition also minimizes the 
lipid peroxidation via reduced peroxynitrite production.  
             Thus  ACE  inhibitors limit the smooth muscle proliferation, and 
carotid intimal thickening as confirmed  by SECURE study due to its 
inhibition of H2O2. Because  ACE inhibitors will minimize H2O2 
production.  H2O2-derived hydroxyl radical and hypochlorous acid (HOCl) 
formation also be decreased by ACE inhibitors. Finally, ACE inhibitors 
reduce the production of oxidants at the source level; issues of scavenging 
efficiency and compartmentalization are not a consideration.                  
Figure-17   Antioxidant activity of  ACE Inhibitors 
           
 
              
 
ROLE OF ACE INHIBITORS IN DOXORUBICIN INDUCED 
CARDIOTOXICITY62,66,67:- 
         Doxorubicin induced cardiotoxicity is mainly attributed due to 
oxidative stress to the myocardium  and later up regulation of ACE activity 
which in turn progress to Angiotensin II mediated  cardiac dysfunction. 
       Since ACE Inhibitors has free radical scavenging activity by inhibiting 
NADPH Oxidase mediated oxidative stress to the endothelium and 
myocytes and also inhibit the ACE over activity in anthracyclines induced 
cardiomyopathy. So it may ameliorate doxorubicin injury to the heart 
because of its dual role in preventing cardiotoxicity. 
       Sacco et al57. have studied that role of zofenopril an ACEI in reducing 
cardiac injury due to the long term doxorubicin administration in rats. After 
oral administration of zofenopril which significantly reduced adriamycin-
induced cardiotoxicity without reduce the antineoplastic activity of 
Adriamycin. 
           Abd el-aziz et al.63 demonstrated the anti oxidative potential of both 
enalapril & captopril in daunorubicin -induced oxidative toxicity in rats. 
This cardio protective effect may be mediated by the limitation of free 
radicals and the amelioration of oxidative stress. Iqbal et al64.demonstrates 
the protective effects of telmisartan against acute adriamycin-induced 
cardiotoxicity in rats.   
Recent trend  in CHF management61 
      An elevated level of oxidant and other forms of inflammatory stress 
observed in patients with CHF may impair vascular reactivity by disruption 
of normal vasodilator cell signaling pathways. Vascular dysfunction is 
associated with decreased exercise tolerance and a poorer clinical outcome. 
This process is in part mediated by increased levels of reactive oxygen 
species, decreased endogenous levels of antioxidant enzymes, and decreased 
levels of bioavailable NO. Preserving normal vascular reactivity is a target 
of evolving priority in the treatment of patients with chronic congestive 
heart failure. Increased levels of reactive oxygen species (ROS), including 
superoxide (O2–) and hydrogen peroxide (H2O2) that are generated in both 
endothelial cells (EC) and vascular smooth muscle cells (VSMC) impair key 
cell signaling pathways necessary for normal vascular function. 
Specifically, hyperaldosterone-induced decreased antioxidant enzyme 
activity in EC, such as glucose-6-phosphate dehydrogenase (G6PD), results 
in increased ROS formation. In EC, elevated levels of ROS impair vascular 
reactivity, in part, by decreasing endothelial nitric oxide synthase (eNOS) 
activity and increasing peroxynitrite (ONOO–) formation to decrease 
bioavailable nitric oxide (NO) levels. 
Figure – 18  Role of ROS in the Pathophysiology of CHF & its prevention 
by different drugs including ACE Inhibitors 
 
Mineralacorticoid (MR)-receptor antagonists, XO inhibitors (XO-I), HMG-
coA–reductase inhibitors (statin), AT1 receptor blockers (ARBs), and 
angiotensin-converting enzyme (ACE) inhibitors block various cellular 
reactions associated with elevated levels of ROS and impaired vascular 
reactivity. 
       However, before a conclusive statement can be made on the potential 
usefulness of ACE Inhibitors as an adjunct to anthracyclines therapy, there 
is a need for further long-term chronic studies with ACE Inhibitors.       
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                              MATERIALS AND METHODS 
The  study  was  undertaken  in  breast cancer patients who undergone  
doxorubicin based chemotherapy,  to find out the  cardio protective effect of  
enalapril  on doxorubicin induced cardiotoxicity by serial monitoring of Left 
Ventricular Ejection Fraction, Fractional Shortening by echocardiogram and 
serum Troponin I level.  
STUDY CENTRE 
   The present study was carried out in the inpatients of Department Medical 
Oncology, Government Rajaji Hospital, Madurai after obtaining clearance 
from Institutional Ethical Committee, Government Rajaji Hospital, 
Madurai. Ref. Letter No. 4105/E4/3 /2013. [Annexure I]. 
COLLABORATING DEPARTMENTS 
 Institute  of  Pharmacology, Madurai Medical College, Madurai. 
 Department of  Medical Oncology, Govt. Rajaji Hospital, Madurai. 
 Department of Cardiology, Govt. Rajaji Hospital, Madurai. 
 Department of  Biochemistry, Madurai Medical college, Madurai. 
 
 
STUDY DESIGN 
It was a single center, open labeled, prospective, interventional study.  
STUDY POPULATION 
Breast cancer Patients admitted in   Department of Medical Oncology, 
Government Rajaji Hospital, Madurai. 
SAMPLE SIZE 
60 adult female breast cancer patients on doxorubicin based chemotherapy, 
divided into two groups, each group comprising 30 patients after satisfying 
the inclusion and exclusion criteria. 
STUDY PERIOD 
     This study was conducted from Feb 2013 to Aug 2014 for 19 months. 
1.  Literature collection               :    3 months 
2.  Designing the study               :     1 month 
3.  Case selection and follow-up  :     12 months 
4.  Analysis  & Interpretation      :     2 months 
5.  Discussion                               :     1 month. 
 INCLUSION CRITERIA 
1. Breast cancer patients of age between 20 – 65 yrs irrespective of 
tumour size, and stage of the disease undergoing doxorubicin based 
chemotherapeutic regimen. 
2. Gender – Female. 
3. Subjects willing for the study. 
 
EXCLUSION CRITERIA 
1. Age more than 65 years. 
2. Male breast cancer patients. 
3. Pregnant &  lactating  women 
4. Patient with H/o hypersensitivity to Enalapril. 
5. Known case of  bilateral renal artery stenosis 
6. Left Ventricular Ejection Fraction  < 50 % by echocardiogram 
7. Ongoing  therapy  with   ACE  inhibitors & angiotensin  receptor  
blockers 
8. Patients with hypertensive, ischemic and valvular heart disease and 
uncontrolled hypertension. 
9. Patients with systolic blood pressure less than 90 mmHg 
10. Patients with hepatic dysfunction - As evidenced by symptomatic 
liver disease or abnormality in liver function tests. 
11. Patient with Chronic kidney disease (Creatinine Clearance ≤ 60 
ml/min.) 
12.  Patient with elevated serum potassium level ≥ 5meq/ l. 
13. Previous participation in a similar study. 
 
INFORMED CONSENT 
   Subjects  who  were  willing  to  participate  were  explained  about  the 
purpose, risks  and     benefits  of  the  study  verbally  before  enrolling  to  
the  study,  in   a language   that   was   easy  to understand by the subject. 
Written informed consent was   obtained    from   all the patients, dated and 
signed by them.  The participants were   provided with   the details of the 
investigator (Name, contact address, phone number), so   that they   may 
contact the investigator for any ailments, which arise due to the intervention.  
 
DISCONTINUATION 
1. Patients were given the freedom to quit the study at any time. 
2. Subjects were withdrawn from the study, if they 
 Develop any serious adverse effects to the drug. 
 Underwent any surgery. 
 Migrate to other place. 
 Fail to comply with the proposed protocol. 
 
METHODOLOGY  
          60 Breast   cancer patients undergoing   doxorubicin contain   
chemotherapy either post operatively as adjuvant therapy or preoperatively 
as neoadjuvant therapy, admitted in the department of medical oncology 
were included for the study. The investigations like complete haemogram, 
blood  sugar, blood  urea, serum Creatinine, serum Bilirubin, serum 
glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic 
transaminase(SGPT), Alkaline Phosphatase (ALP),Serum Proteins, 
Electrocardiogram(ECG) , serum electrolytes were done. A baseline 
assessment of plasma troponin I (TnI) level was measured by ELISA 
method. Left ventricular ejection fraction (LVEF) & Fractional Shortening 
(FS) were measured by echocardiogram. Patients with  LVEF >50%  were 
taken in to the study. Patients were allocated into two groups. Each group 
comprising 30 patients.   
 
GROUP I (CONTROL - WITHOUT ENALAPRIL)  
 Inj.Doxorubicin 50mg/m2    intravenously   once  in  21 days  for  6 
cycles   
 Inj.Cyclophosphamide 500mg/m2 intravenously once in 21days for 6 
cycles. 
 Inj.5-Fluorouracil 500mg/m2   intravenously once in 21 days for 6 
cycles. 
GROUP II (ENALAPRIL) 
 Inj.Doxorubicin  50mg/m2  intravenously  once  in  21 days   for  6 
cycles, 
 Inj.Cyclophosphamide 500mg/m2 intravenously once in  21 days for 6 
cycles 
 Inj.5-Fluorouracil 500mg/m2   intravenously once in 21 days for 6 
cycles. 
 Tab. Enalapril  5 mg / once  daily  at bed time  started  after the 6th 
cycle of chemotherapy schedule and slowly titrated upto 10 mg once 
daily and continued  for  6 months. 
Cardiac assessment was done by measuring Troponin I level at baseline, 24 
hrs after first dose of chemotherapy and at the end of the chemotherapy 
schedule (6th cycle).  Cardiac function was also evaluated by serial 
measurement of   LVEF and FS  by echocardiogram  at baseline, 3rd 
cycle,6th cycle, 6th month and 9th  month of the study.    
VISIT 1 [BASELINE]  
Patients were reviewed after one week of screening and they underwent the 
Following: 
 Obtained informed written consent. 
 Recorded height, weight and calculated BSA. 
 Performed physical examination. 
 Measured vital signs - Pulse rate, Blood pressure as per method 
described above.  
 Performed  a  detailed  systemic  examination 
 Obtained  blood  samples  for  laboratory  tests  [Blood  sugar,  
blood  urea, serum Creatinine, Serum electrolytes, Liver function 
tests, Hb%, Troponin I] and urine sample for albumin, Sugar and 
deposits. 
 Evaluated the left ventricular ejection & fractional shortening by 
ECHO. 
 Dispensed the study  drug to  the test group for  every 21  days for a 
period of 6 months after end of doxorubicin schedule and  instructed  
the patient to take enalapril and explained about the dose and time of 
intake. 
 Informed about the possible adverse reactions to drug therapy and 
were given the investigator’s details for reporting. 
 The  date  of  treatment  initiation  was  documented  and  the  
patients  were advised  not  to  take  any  medication  without  the  
knowledge  of  the invigilator. 
 The subjects were asked to bring the utilized drug strips during their 
next visit to ensure their compliance. 
SUBSEQUENT VISITS 
During subsequent visits,  
 Patients were reviewed once in 21 days. 
 The patients were enquired about the well being. 
 Used strips of the study medication dispensed during previous visit 
were collected and checked. 
 Recorded blood pressure and pulse and systemic examination was 
performed. 
 The patients were assessed for any adverse events. 
 The study drug was given for the 3 weeks. 
 After the end of  6th month, all the clinical tests performed during the 
initial visit were repeated. 
END OF THE STUDY 
At the end of 9th month all investigations were done during  the  initial  
recruitment  were  repeated,  and  ECHO  was  also performed to assess the 
left ventricular ejection fraction and fractional shortening. The treatment 
efficacy  was  monitored  with  echocardiography assessment. The 
tolerability of the drugs was monitored by assessing adherence to treatment, 
serum potassium levels and any adverse reactions noticed either by the 
patients or by the invigilator. 
STATISTICAL ANALYSIS 
The data were analyzed with SPSS statistical software package (Version 
16.0 SPSS  Inc.,  Chicago,  USA).  The  results  were analyzed using 
Student’s “independent”  t  test for  between the groups and Student’s 
“paired” t  test for within the group.  P  < 0.05 will be considered as 
statistically significant. 
 
   
 
  
 
 
 
 
 
  RESULTS 
 
 
                                              RESULTS  
     Totally 60 female breast cancer patients, 30 in each group   were 
recruited for the study. All the 60 patients were followed up to the end of 
the study. There was no drop out from the study.  
      Among the 60 female patients who completed the study, the age related 
distribution were as follows, In the enalapril group 16.6%  patients were in 
the age group 30-39 years, 20% patients were in the age group 40-49 years, 
30% patients were in the age group 50-59 years, 33.3% patients were in the 
age group  > 60 years.  
         In control group (without Enalapril) 16.6% patients each were in the 
age group 30-39 and 40-49 years, 33.3% patients each were in the age group 
50-59 and  > 60years. The majority of patients belonged to > 60 years of age 
(33.3%) in both the groups.  
   The mean age of the patients in the control group was 53.33 ± 9.58 years. 
The mean age of the patients in enalapril group was 52.13 ± 9.80 years. 
                                     
 
 
 
Table - 10    Age  distribution  of the participants 
Age (years)                                   Number of patients 
             Control group          Enalapril group 
    30 – 39                          5                          5 
    40 – 49                          5                                             6 
    50 – 59                         10                          9 
     >60                         10                        10 
   Total                          30                        30 
 
Figure – 19  Age distribution of the participants         
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BASELINE PARAMETER 
The following table shows the baseline characteristics of the patients in the 
both group included in the study. 
Table -  11  Baseline characteristics of  the participants 
 
      PARAMETER 
                        Mean ± SD 
 Control     Group  
 (without Enalapril)  
    Enalapril 
      Group 
Age (years)         53.33 ± 9.58      52.13 ± 9.8 
BSA (m2)         1.61 ± 0.12      1.62 ± 0.09 
Number of chemotherapy cycles                 6              6 
Cumulative doses of doxorubicin        484 ± 36.93     486± 28.35 
Baseline  Heart  rate         87.56  ± 10.32     89.02 ± 11.63 
Baseline  Systolic BP (mm Hg)        124.14 ± 13.52     128.06± 11.17 
Baseline  Diastolic BP (mm Hg)        81.23 ± 7.92     80.42 ± 9.07 
Baseline Troponin I (ng/ml)        0.29 ± 0.14     0.25 ± 0.13 
Baseline LVEF (%)        61.63 ± 2.98     61.45± 2.82 
Baseline Fractional Shortening 
(%) 
       33.73 ± 2.22     34.03 ± 2.27 
 
 
CUMULATIVE DOXORUBICIN DOSE 
  The mean cumulative doxorubicin dose of the study subjects at the end of 
the chemotherapeutic schedule (6th cycle) in Enalapril group and control 
group  were 486 ± 28.35 and 484 ±36.93 respectively which is statistically 
not significant. 
Figure – 20    Mean cumulative doxorubicin dose 
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 TROPONIN I  
     Troponin I was used to categorize the high risk group as an early marker 
of  myocardial injury. Plasma troponin I was measured using ELISA 
technique. After standardization the cut off value was determined as   1 
ng/ml.   The value  > 1ng /ml was considered as early myocardial injury. 
      Average Troponin I value at baseline in Enalapril & control group was 
0.25± 0.13 & 0.29± 0.14 ng/ml  respectively. Within 24 Hrs of  Doxorubicin 
infusion Troponin I level were elevated to 0.67± 0.60 &  0.63± 0.59 ng/ml 
in both the groups.  
         At the end of the chemotherapy schedule mean Troponin I value were 
0.64±0.55 & 0.77±0.73 in both the groups respectively. 23.3% of patients in 
both the groups showed persistent elevation of Troponin I level and were 
more prone for cardiotoxicity and those subjects were considered as High 
risk groups. 
   
 
 
 
    
Table – 12   Patients  with  Persistent  Troponin  I  Elevation 
  
Timing of  Troponin I 
No of  patients  with  persistent  Troponin I     
                                Elevation 
      Control   group     Enalapril    group 
24 hrs after doxorubicin                9 ( 30% )         8     ( 26.7% )  
End  of  CT schedule                7 ( 23.3% )          7    ( 23.3% ) 
                
Table – 13  Plasma Troponin  I   values  in both the groups 
Timing of  Tn I 
tested 
Troponin  I   value ( ng/ml)  (mean ±SD) 
Control     
Group  
Enalapril  
Group 
T value df P value 
Baseline   0.29± 0.14  0.25± 0.13  -0.960 58 0.341 
24hrs after first dose  0.63± 0.59  0.67± 0.60   0.257 58 0.798 
6th cycle  0.77±0.73  0.64±0.55  -0.724 58 0.472 
 
*Significant if  P < 0.05 
   
 
  
Figure – 21 Plasma Troponin  I   values  in both the groups 
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EJECTION FRACTION 
         Ejection Fraction is an important parameter to evaluate left ventricular 
function in doxorubicin induced cardiotoxicity. Hence Left ventricular 
function was monitored by serial measurement of Ejection Fraction with the 
help of Echocardiogram. The mean LVEF between groups were compared 
at baseline, 3rd, 6th cycle, 6th and 9th month of the study. 
      The mean LVEF at baseline , 3rd cycle and 6th cycle in both the groups 
were 61.47  ± 2.82 & 61.63 ± 3.02; 58.8± 3.16 & 58.87±3.50;  56.63 ± 4.10 
& 56.83 ± 3.76  respectively. Comparison of LVEF between these groups 
were statistically  not significant on “independent” t test. But within their 
respective groups they were statistically significant on students “paired” t 
test. The mean LVEF at 6th month in Enalapril treated group and control 
group were 60.20 ± 2.87 and 55.93 ± 4.33 respectively. Comparison of  
LVEF between these two groups showed that Enalapril treated group 
showed statistically significant improvement in LVEF  than in control group 
( P  <0.05).  
         The mean LVEF  at 9th month in Enalapril treated group and control 
group were 61.90 ±2.34 & 54.57 ± 5.86 respectively. Comparison of LVEF 
between these two groups showed that Enalapril treated group showed 
statistically significant improvement in LVEF than in control group ( P 
<0.05).    
Table –  14   Changes in Left ventricular ejection fraction 
Timing of 
ECHO 
                      LVEF (%)  MEAN ± SD 
Control Group Enalapril Group tvalue df p value 
Baseline 61.63  ± 3.02 61.47  ± 2.82 -0.221 58 0.619 
3rd  Cycle of CT 58.87  ± 3.50 58.80  ± 3.16 -0.077 58 0.819 
6th Cycle of CT 56.83  ± 3.76 56.63  ± 4.10 -0.197 58 0.969 
6th Month 55.93  ± 4.33 60.20  ± 2.87  4.493 58 0.023* 
9th Month 54.57  ± 5.86 61.90  ±2.34  6.362 58 0.001* 
*Significant P <0.001 
Figure  – 22  Changes in Left ventricular ejection fraction 
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FRACTIONAL SHORTENING 
       Fractional shortening is an another important parameter to evaluate left 
ventricular function in doxorubicin induced cardiotoxicity. Hence in this 
study, Left ventricular function was monitored by  serial  measurement of 
Fractional Shortening with the help of M mode Echocardiogram. The mean 
FS between groups were compared at baseline, 3rd ,6th cycle, 6th and 9th 
month of the study. 
     The mean FS at baseline, 3rd cycle and 6th cycle  in both the groups were 
34.03 ± 2.31 & 33.73± 2.56 ; 32.23 ± 2.10 & 31.90 ± 2.31; 30.77 ± 2.90  &  
30.63 ± 2.51 respectively. When a change in FS was compared between 
these groups, they were not significant statistically on “independent” 
student’s t test. But within their respective groups they were statistically 
significant on student’s “paired” t test. The mean FS  at 6th month  in 
Enalapril treated group and control group were 32.87 ± 2.53 and 29.60 ± 
2.55 respectively. On comparing FS between these two groups Enalapril 
treated group showed significant improvement in FS  than in control group ( 
P <0.001 ). 
          The mean FS at the end of study (9th month),  in Enalapril treated 
group and control group were  34.07 ±2.21 &  28.97 ± 3.47 respectively. 
When FS is compared between these two groups Enalapril treated group 
showed significant improvement in FS than in control group (P <0.001). 
Table – 15   Changes in the Fractional Shortening 
   Timing  of     
     ECHO 
                         FS(%)  MEAN ± SD 
Control Group Enalapril Group t value df P value 
Baseline 33.73  ± 2.26 34.03 ± 2.31 0.508 58 0.613 
3rd  Cycle of CT 31.90  ± 2.31 32.23 ± 2.10 0.585 58 0.561 
6th Cycle of CT 30.63   ± 2.51 30.77± 2.90 0.199 58 0.843 
6th Month 29.60 ± 2.55 32.87 ± 2.53 4.978 58 0.001* 
9th Month 28.97 ± 3.47 34.07 ±2.21 6.776 58 0.001* 
       *Significant P <0.001 
Figure  –23  Changes in the Fractional Shortening 
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PERCENTAGE OF REDUCTION LVEF  & FS  OVER THE STUDY 
PERIOD 
               At the end of the chemotherapy schedule (6th cycle), LVEF fell by 
7.87% (56.63 ± 4.1)  and 7.8% ( 56.83 ± 3.76 )in both the groups from the 
baseline LVEF  (61.47 ± 2.82 & 61.63  ± 3.02 ) respectively . After 
intervention with enalapril, at 6th month the average LVEF was reduced by 
2.06% (60.20± 2.87) and at the end of  the study it was above the baseline 
(61.9±2.34 ). In control group, at 6th month the average LVEF was reduced 
by 9.2% (55.93 ± 4.33 ) and at the end of  the study it had fell to 11.4% 
(54.57 ± 5.86) from the baseline value. 
     At the end of the chemotherapy schedule (6th cycle), FS fell by 9.4 % 
(30.77±2.9) and 9.2% (30.63 ± 2.51) in both the groups from the baseline 
FS (34.03±2.31 & 33.73±2.26) respectively. After intervention with 
enalapril, at 6th month the average FS was reduced by 3.3% (32.87 ± 2.53) 
and at the end of  the study it had reached above (34.07 ±2.21) the baseline 
value. In control group, at 6th month the average FS was reduced by 12.2% 
(29.60 ± 2.55) and at the end of the study it had fell to 14.1 % (28.97 ± 3.47) 
from the baseline value. 
 
 
  Table – 16  Percentage of  Reduction LVEF over the study period 
Ejection 
Fraction 
 Control  group           Enalapril  group 
Mean 
LVEF 
%of 
reduction 
Mean 
LVEF 
%of 
reduction 
Baseline 61.63± 3.0 0 % 61.47± 2.8  0 % 
3rd cycle 58.87±3.5 Ļ4.5% 58.8 ± 3.16 Ļ4.3% 
6th cycle 56.83± 3.7 Ļ7.8% 56.63 ± 4.1 Ļ7.8 % 
6th month 55.93 ± 4.33 Ļ9.2% 60.20± 2.87 Ļ2%(↑5.9%) 
9th month 54.57± 5.86 Ļ11.4% 61.90±2.34 0% (↑8.5%) 
 
Table – 17   Percentage of reduction FS over the study period 
Ejection 
Fraction 
 Control group Enalapril group 
Mean FS    %of 
reduction 
Mean  FS     %of 
reduction 
Baseline 33.73±2.26 0 % 34.03±2.31 
 
  0 % 
3rd cycle 31.9±2.31 Ļ5.4% 32.23±2.1 Ļ5.2% 
6th cycle 30.63 ± 2.5 Ļ9.2% 30.77±2.9 Ļ9.4 % 
6th month 29.6 ± 2.55 Ļ12.2% 32.87 ± 2.53 Ļ3.3%(Ĺ6.3%) 
9th month 28.97 ± 3.47 Ļ14.1% 34.07 ±2.21 0% (Ĺ9.6%) 
 
Figure  -24   Percentage of  Reduction    LVEF   over the study period 
 
Figure – 25 Percentage of reduction FS over the study period 
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SUBCLINICAL TOXICITY 
Tough clinical manifestations of doxorubicin induced cardiotoxicity 
manifest when its cumulative dose exceeds > 450 mg/m2, sub clinical, 
asymptomatic cardiotoxicity increases by adding each dose of doxorubicin. 
Sub clinical toxicity defined as more than 10% reduction of LVEF and 
fractional shortening from its baseline value during serial echocardiogram 
evaluation. 
 In this study  
Table – 18  No. of  patients with  LVEF  < 50%  & FS < 25% 
Timing  of  
ECHO 
 No. of  patients with  LVEF  < 50%  & FS < 25% 
      Control group    Enalapril group 
End of CT            3  ( 10% )            2  ( 6.7 % ) 
End of study           6  ( 20% )          0   ( 0%  ) 
 
Table – 19  No. of  patients with  > 10 %  reduction in LVEF & FS 
Timing  of   
ECHO 
No. of  patients with  > 10 %  reduction in LVEF & FS 
         Control group        Enalapril  group 
End of CT                7  (23.3%)              7  (23.3%) 
End of study             11  ( 36.7%)              1  ( 3.3%) 
 
Table – 20   Cardiac  events  during  entire  study period 
             EVENTS     Total Control  
Group 
 Enalapril  
Group 
ECG changes (Non 
specific) 
       11         8                  3 
Arrhythmia   requiring    
       treatment 
       3         3                  0 
Heart failure treated        2         2                  0 
Hypotension required 
Enalapril dose reduction / 
treatment 
       3         2                  1 
Hyperkalemia         Nil         Nil                  Nil 
Abnormal RFT        Nil         Nil                  Nil 
Abnormal LFT        Nil         Nil                  Nil 
 
     
 
 
 
  
Figure – 26   Cardiac  events  during  entire  study period 
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 Table - 21 
Cardiac events in patients  with  persistent  Troponin  I  elevation 
            Cardiac events Control   
Group 
 Enalapril     
    group                 
No   of  patients  7 (23.3%)   7 (23.3%) 
Patients with H/O Mediastinal 
irradiation 
 4(13.3%)   3(10%)  
LVEF <50%   
& FS <25% 
End of CT   3 ( 42.8% )    2  ( 28.5 % ) 
End of study  5 ( 71.4% )    0  ( 0%  ) 
> 10 %  reduction in LVEF & FS  7 (100%)    1 ( 14.3%) 
ECG changes (Non specific)  5 ( 71.4% )       2 ( 28.5 % ) 
Arrhythmia   requiring   treatment  3 ( 42.8% )    0 (0%) 
Heart failure treated  2 (28.6%)    0 (0%) 
Hypotension required treatment  2 (28.6 % )    1 (14.3%) 
 
 
 
 
 Figure – 27 Cardiac  events in patients  with  persistent  troponin  I  
elevation 
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                                     ADVERSE EFFECTS   
The following adverse effects noted in enalapril treated group:- 
       Alopecia (30%), Nausea & Vomiting (24%), Mucosal ulcer (11%),  
Skin Rashes(8%), Diarrheoa(7%), Leucopenia( 6%), Anaemia(5%), ECG 
changes( 4%), Cough (2%), Extravasations, Arrhythmia and Hypotension 
each 1%.These are shown in pie diagram. 
Figure – 28 Adverse effects noted in enalapril group 
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The following adverse effects noted in Control Group:- 
   Alopecia (29%),Nausea & Vomiting (19%),Mucosal ulcer (11%), Skin 
Rashes(9%), Diarrhea(3%), Leucopenia(6%), Anaemia(5%), ECG 
changes(9%), Extravasations(2%), Arrhythmia(3%), Hypotension(2%), 
Congestive Heart Failure( 1%.). These  are shown in pie diagram. 
Figure – 29 Adverse effects noted in control group 
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DISCUSSION 
 
 
 
                                     DISCUSSION 
      Breast cancer is the most common cancer among females in developed 
countries like USA and UK. It is the second most common cancer of 
females after cervical cancer in developing countries like India. From  the 
last decade onwards the incidence of  breast cancer in urban populations 
increased dramatically. It is mainly due to western life style, changes in the 
food habits, sedentary life style, obesity, smoking habit and alcohol intake. 
Surgery is the primary modality of treatment in early breast cancers. For 
advanced stages adjuvant therapies like radiotherapy, chemotherapy and 
hormonal therapy are commonly used to prevent the metastasis and to 
prolong the disease free interval. Among chemotherapy anthracyclines 
based combination chemotherapy is commonly used to treat breast cancer 
because it is highly efficacious in reducing the tumor burden. 
         Doxorubicin is an antitumor antibiotic with wide spectrum of activity 
over the many neoplastic disorders including carcinoma of breast. Since 
1970 its introduction as a cancer chemotherapeutic agent, it is one of the 
main component of various chemotherapeutic regimen in most of the solid 
cancers, hematological neoplasm’s, lymphomas, sarcomas and carcinomas 
including breast cancer.  
               Drug induced cardiotoxicity is a rapidly evolving condition 
because of number of cancer survivors has been increased. Doxorubicin 
induced cardiotoxicity is mainly due to dose dependent cumulative toxicity 
via free radical injury and oxidative stress to the cardiac myocytes. 
Doxorubicin can cause acute reversible cardiotoxicity and delayed 
irreversible cardiomyopathy years after doxorubicin therapy. Prevalence of 
doxorubicin induced cardiotoxicity is not known. Worldwide, the overall 
incidence of this cardiotoxicity is underestimated because of its delayed 
presentation. The onset of asymptomatic & subclinical66 cardiotoxicity not 
only negatively impacts the cardiac outcome of breast cancer patients and 
also   limits their therapeutic opportunities seriously. 
               Early prediction of cardiotoxicity by identifying high risk groups 
by measurement of cardiac biomarker like Troponin I soon after 
doxorubicin therapy, patients with elevated Troponin I are the greatest risk 
of development of cardiotoxicity in future eventhough asymptomatic at 
early stages. So it is mandatory to evaluate cardiac function of the patients 
undergoing doxorubicin therapy by means of serial measurement of left 
ventricular ejection fraction and fractional shortening by echocardiogram 
before, during and after doxorubicin therapy periodically and early 
intervention will prevent or delay the development of chronic 
cardiotoxicity. By prophylactic administration of  Enalapril67, an 
Angiotensin Converting Enzyme Inhibitor  in high risk groups minimize 
the cardiovascular morbidity and mortality in different clinical settings 
including doxorubicin induced cardiotoxicity50,55,62 by inhibiting 
Angiotensin II mediated oxidative stress to the cardiomyocyte, cardiac 
remodeling and cardiac hypertrophy .  
    With this background the present study was undertaken to find out the 
effect of doxorubicin on cardiovascular system and to evaluate the cardio 
protective effect of enalapril on doxorubicin induced cardiotoxicity in a 
tertiary care center in south Indian population. 
     This study was undertaken in 60 female patients who were diagnosed as 
breast cancer, irrespective of the size and stage of the cancer were recruited 
and allocated into 30 in each group as per the protocol. Baseline 
investigations like complete haemogram, blood sugar, blood urea, serum 
Creatinine, serum Bilirubin, serum electrolytes were done. Cardiac function 
was assessed by ECG, plasma troponin I level. Patients with  LVEF >50% 
& FS >25% were included for the study. Both the groups received six cycles 
of chemotherapy containing doxorubicin, cyclophosphamide & 5-
Fluorouracil. 
      In the present study the mean age of participants in enalapril and without 
enalapril group respectively were 53.3±9.5 & 52.1±9.8 years. Majority of 
patients belonged to post menopausal age group between 50 – 65 years in 
both the groups.  
      Cardinal et al. demonstrated that TnI elevation soon after doxorubicin 
chemotherapy predicts cardiotoxicity and its poor cardiological outcome 
earlier, with more risk observed in patients having persistent TnI 
elevation7. 
     In the present study TnI measured at baseline, 24hrs after first dose of 
doxorubicin and at the end of chemotherapy schedule (6 th cycle) used to 
predict early myocardial injury. 26.7% & 30% of subjects in both the 
groups were showed elevated TnI after 24 hrs. 23.3% of the participants 
in both the groups showed persistent elevation of TnI at the end of 
chemotherapy schedule were considered as high risk patients. These 
findings are similar with cardinal et al11 study. 
             After the completion of six cycles of chemotherapy first group 
consists of 30 patients were started Enalapril 5mg/day orally at bedtime 
and the dose gradually increased up to 10 mg per day continuously for 6 
months. Remaining 30 patients did not receive enalapril and both group 
of patients were observed for 9 months.  
        Doxorubicin induced subclinical and clinical cardiotoxicity was 
monitored by ECG, Ejection fraction & Fractional shortening by 
echocardiogram at 6th and end of the study (9th month) in all these 
participants. Left ventricular function was monitored by serial 
measurement of LVEF & FS by echocardiogram. In this study both these 
parameters were monitored at baseline, end of chemotherapy schedule, 6th 
& 9th month of the study. 
     Normal ejection fraction value is between 50-70%.Normal fractional 
shortening value is between 25-45%. Symptoms of Left ventricular 
dysfunction occur when LVEF < 45% & FS < 25%. 
       In the present study, patients treated with enalapril showed statistically 
significant improvement in LVEF & FS as compared with patients without 
enalapril. When compare LVEF & FS between these two groups, mean 
LVEF & FS were gradually decreased in control group at the end of 
doxorubicin schedule, 6th month & 9th month of the study   from the 
baseline value which is statistically significant (p < 0.001). These findings 
are similar with cardinal et al11 study. 
       In enalapril treated group mean LVEF & FS were gradually increased 
at the 6th month and 9th month of the study from  the mean LVEF & FS at 
the end  of chemotherapy cycle which is statistically significant (p < 
0.001).At the end of the study mean LVEF is attained the baseline value in 
enalapril treated patients.  
    In control group both LVEF & FS was gradually reduced to 7.8% & 
9.2%; 9.2% & 12.2%; 11.4% & 14.1% respectively at the end of 
chemotherapy,6th & 9th month of the study from the baseline value. But in 
enalapril treated group both LVEF & FS was gradually increased to 5.9% 
& 6.3% at 6th month, 8.5%&9.6%  at 9th month respectively compared to 
the values at the end of chemotherapy (6th cycle) . Both LVEF & FS 
reaches the baseline value at the end of 9th month.   
       Asymptomatic, subclinical cardiotoxicity 66,68, is  defined as more than 
10% reduction in LVEF & FS from the baseline value and those LVEF & 
FS values are >50% & >25% respectively. The patients with subclinical 
toxicity are more prone to develop congestive cardiac failure and 
cardiomyopathy in future. 
  In this study 36.1% patient & 3.3% patients in control and enalapril 
treated groups showed sub clinical cardiotoxicity by means of more than 
10% decrease in both LVEF & FS from the baseline value. These findings 
are comparable with khattry et al68 study findings.     
  At the end of 9th month 20% of patients in control group showed both 
LVEF & FS less than 50% & 25%. But in enalapril treated group all the 30 
patient’s L↑EF & FS were above the normal value.  
      ECG changes like sinus tachycardia, prolonged PR interval, T wave 
inversion were seen in 10% & 26% of patients in enalapril treated and 
control groups respectively. All these changes were reverting to normal in 
both these groups. Arrhythmias developed in 10% of patients in control 
group and were treated successfully. Symptomatic heart failure occurred in 
2 persons (6.6%) in control group and was treated. No one developed 
arrhythmia & CHF in enalapril treated group. Hypotension was developed 
in one patient in each group, enalapril dose was reduced from 10mg to 5mg 
in enalapril treated patient and also treated with IV fluids.  
 
Cardiac events in high risk group (elevated TnI):- 
At the end of 9th month ,5 patients (71.4% ) showed LVEF <50% & FS < 
25% out of 7 patients showed persistent TnI elevation in control group, 
none in enalapril treated group. Sub clinical cardiotoxicity were found in 
100% & 14.3% respectively in control & enalapril treated high risk group 
category. CHF, Arrhythmia, Hypotension were developed in 28.6%,42.8% 
&14.3% respectively in high risk control group,0%,0% & 14.3% in 
enalapril treated high risk group. These findings are similar with cardinal et 
al.11 study. Most of these cardiotoxicity occurred in age more than 55 yrs, 
cumulative dose more  than 450mg/m2, and  H/O mediastinal irradiation. 
       Common adverse effects noted in both groups were alopecia, nausea 
and vomiting, mucositis, diarrhea and rashes. 
      The role of cardiac Renin Angiotensin System in the formation of 
doxorubicin-induced cardiotoxicity is documented in experimental 
models. Cardiac ACE activity was elevated after doxorubicin therapy 
compared with control subjects in those models. In an animal model 
lisinopril given after doxorubicin therapy significantly decrease the 
cardiac ACE activity. Lisinopril also improved the cardiac function, 
mortality, reduced the ventricular remodeling. Collagen accumulation 
and fibrosis was inhibited in the cardiac muscle in temocapril treated 
rats. These findings suggest that activation of ACE plays an important 
role in the development of cardiotoxicity. So ACEIs beneficial effects in 
doxorubicin- treated animals depend on its inhibition of  cardiac ACE. 
      Enalapril had been shown to have antioxidant property by its free 
radicals scavenging activity. An oxidative stress is a possible mechanism in 
the formation of doxorubicin induced cardiomyopathy. Hence both 
Sulfhydryl- and non–Sulfhydryl-containing ACEIs may be effective in the 
prevention of doxorubicin -induced cardiotoxicity because of its free radical 
scavenging potential on cardiomyocyte. 
            Cardiac tissue RAS stimulation and oxidative stress to the 
myocardium may be involved in the progression of doxorubicin -induced 
cardiac injury. Hence by limiting these mechanisms with enalapril, may be 
useful to prevent the development of cardiac dysfunction. 
     The present study resu l t s  confirm the prognostic role of TnI as an 
early marker to find out the high-risk patients. Prophylactic enalapril 
administration has been showed to preserve the left ventricular function & 
improved cardiological outcome. Neither fractional shortening nor LVEF 
altered during the treatment period in the enalapril treated group, and 
lower incidence of cardiac events was observed than in untreated 
patients.  The benefits of ACEIs have been defined in hypertension, acute 
myocardial infarction, and asymptomatic left ventricular dysfunction and 
in chronic heart failure.  Use   of enalapril has been proved to be beneficial 
in prolonging survival and in preventing further deterioration of cardiac 
function in anthracycline- induced cardiotoxicity. 
           Untreated patients having a persistent TnI increase after the end of 
doxorubicin therapy have progressive LVEF reduction than in patients 
with normal TnI level.  Benefit of enalapril treatment was present in both 
subgroups, but patients with a persistent TnI elevation may particularly 
benefit from enalapril therapy. Enalapril was very well tolerated in all the 
patients because of very slow and careful titration may have contributed 
to this result. 
Different strategies have been implicated to reduce or  to prevent 
cardiac toxicity. Like close monitoring of cardiac function, modification 
in doxorubicin schedule administration, minimize the doxorubicin 
cumulative dose, doxorubicin analogue usage and use of 
cardioprotectants like antioxidant agents, dexrazoxane have been 
followed. However, each of these approaches has its own limitations 
such as the possible compromising of antitumor efficacy, poor predictive 
value and high costs.   
Study Limitations 
           Although this t r i a l  was designed as a prospective study, the lack 
of placebo administration, open-label follow-up were potential limitations 
of this study. However, the percentage of  pat ients  t reated  wi th  
doxorubicin  schedule, and  the doxorubicin cumulative doses were well 
balanced in both the groups. Hence a different risk of cardiotoxicity in both 
the group is unlikely. 
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                          SUMMARY AND CONCLUSION 
       Breast cancer is the second most common cancer of females in India 
next to cervical cancer. It is managed by multi model approach like surgery, 
radiotherapy, chemotherapy & hormonal therapy. Chemotherapy is used to 
prevent tumor progression & to prevent tumor recurrence.  
        Doxorubicin is  the most active agent for the treatment of carcinoma 
breast. However, its use is limited by cumulative, dose related 
cardiotoxicity. Cardiotoxicity causes in a irreversible loss of cardiomyocyte 
and a progressive deterioration of left ventricular function following 
subsequent dose of doxorubicin therapy. Initially, it causes subclinical 
damage to the heart. However later it impairs cardiac function and result in 
serious cardiac injury leading to chronic heart failure and cardiomyopathy 
which is irreversible.  
       The mechanism of anthracyclines induced cardiotoxicity is not well 
understood till now. But the most accepted one is free radical injury 
mediated lipid peroxidation and oxidative stress to the myocardium which 
induces the apoptosis of cardiomyocyte and results in cardiac dysfunction. 
Some preclinical studies found that increased level of Angiotensin 
converting enzyme (ACE) during doxorubicin induced myocardial damage 
which stimulates angiotensinogen II mediated NADPH oxidative stress 
results in cardiac remodeling and heart failure. From this Renin Angiotensin 
System (RAS) may also take part in the doxorubicin induced myocardial 
injury. So early detection and treatment of cardiotoxicity can reduce its 
cardiovascular  morbidity and mortality which will occur  later.  Various 
strategies were used to reduce doxorubicin induced cardiotoxicity including 
alteration of doxorubicin dosing schedule, using liposomal formulations, 
reducing cumulative doxorubicin dose less than 450mg/m2 , using 
anthracyclines analogues like epirubicin ,using non anthracycline 
chemotherapeutic regimen. 
   Though dexrazoxane – an  iron chelating agent is used to treat doxorubicin 
induced cardiotoxicity after cumulative dose of 300mg/m2,its long term 
protective effect on prevention of delayed cardiotoxicity is uncertain. Few 
trials  found that it also reduce the anti tumor effect of anthracyclines if we 
used concurrently and its long term use may increase the incidence of 
secondary leukemia. So it should be used with caution because of lower 
response rate and the additional costs of  the treatment.  
       Angiotensin converting enzyme inhibitors (ACEIs) are commonly used 
to treat hypertension, coronary artery disease, congestive heart failure. It  is 
one among few group of drugs used to reduce the cardiovascular morbidity 
and mortality in various clinical settings. Its mortality reducing benefit is 
mainly due to its prevention of Angiotensin II mediated NADPH oxidase 
induced cardiovascular changes and improves cardiac left ventricular 
function. So most of the ACEIs including Enalapril has free radical 
scavenging activity by preventing NADPH oxiadase induced lipid 
peroxidation in cardiomyocyte. So Enalapril was used in this study to limit 
the doxorubicin induced cardiotoxicity since it has antioxidant property and 
also ameliorates RAS mediated cardiovascular dysfunction. 
      Cardiac Troponin I is  commonly used to identify  myocardial injury at 
the earliest and used to pick up the high risk patients who are receiving 
conventional doxorubicin therapy. In this study  24% of patients in each 
group showed persistent elevation of Tn I  at the end of doxorubicin based 
chemotherapy schedule. Most  of the cardiac events occurred in this high 
risk patients compared to patients with transient TnI elevation  and those 
showed normal TnI value. 
        In the present study shows the prognostic role of TnI and have 
preserved left ventricular function and an improved cardiological 
outcome when prophylactic therapy with enalapril is carried out. 
       From this we can conclude enalapril has therapeutic value in 
doxorubicin induced cardiotoxicity. Early identification of asymptomatic 
subclinical cardiotoxicity by monitoring   LVEF  & FS  with the help of  
echocardiogram, and  prophylactic administration of Enalapril can 
improves left ventricular function and to delay the progression of 
delayed irreversible cardiotoxicity in patients exposed to the doxorubicin 
for life saving  anti cancer therapy.  
         Further long term, large population based multicenter studies need 
to be carry out to confirm the enalapril role in prevention of doxorubicin 
induced cardiotoxicity. 
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ANNEXURES 
 
 
 
 
 
 
 
 
                                           PROFORMA 
Name:-              Age:-  
Sex :-                                                                               IP No:- 
Occupation:- 
Address:-                                                                          Phone no:- 
H/o presenting illness :- 
Swelling – Onset,Duration  
Pain -  
Discharge  
Axillary Swellings  
H/O Metastasis  
Past history :- 
Any H/o Comorbid Illness:- 
Family H/O :- 
Menstrual history  :-  
Personal History :- 
Treatment History :- 
Drug History:- 
General examination 
Height :                     Weight :                                        BSA:-                         
O/E 
Conscious 
Oriented 
Pallor  
Cyanosis 
Clubbing 
Pedal edema 
Generalized lymphadenopathy 
VITALS 
Pulse :                                                              B.P    :  
R.R :                                                                Temp : 
Examination of  breast &  axilla : 
Nipple & Areola – Discharge, Ulcer  
Skin Over Breast -   Dimpling,Retraction  
Lump – Site , Size, Margins & Fixity  
Lymphnodes – Number, Fixity  
Systemic - Liver Spine/Bone  
CVS- 
RS- 
P/A- 
CNS- 
BASELINE INVESTIGATIONS 
FNAC :-  
Mammogram :-     
Chest radiograph:- 
Receptor status:-  
 ECG:-   
 Complete hemogram:-    
 
 
 
 
 
 
Parameter  Baseline  3rd month  6th  month 9th month 
LFT     
Blood  urea     
Serum  creatinine     
Serum Potassium      
Blood  sugar     
Urine  albumin,  
sugar, specific gravity, 
    
CARDIAC PROFILE. 
Parameter Baseline After  24 hrs  6th Cycle 
Troponin I  Level 
   
 
Echocardiogram 
 
Baseline 3rd Cycle 6th  Cycle 6th  Month 9th Month 
           LVEF     
 
           FS 
     
 
ANY  ADVERSE EFFECT 
 
 
 
 
 
 
 
 
 
                   INFORMED CONSENT FORM IN ENGLISH 
 
Full name of the patient(in capital letters):   __________________________          
Address:______________________________________________________   
__________________________________Date of Birth:______________       
Patient no:_____________  Sex :________    I  freely  agree  to  participate  
in  the above – mentioned clinical study. 
My doctor_____________________ informed me in a personal counseling 
interview about the study drug, possible side effects and risks, the nature, 
objective and significance  of  this  clinical  study  and  my  responsibilities  
resulting  thereof.  In addition,  I  read  and  understood  the  contents  of  
the  Patient  Information  Sheet and Informed Consent Form. The doctor 
answered all questions in an adequate and comprehensible manner. I had 
sufficient time to decide on my participation in  this  clinical  study.   
I  will  follow  the  instruction  of  my  doctor,  which  are essential for the 
performance of this clinical study. I have the right to withdraw from  the  
study  at  any  time  without  giving  any  reason  and  without  any 
disadvantage for me.I confirm that I have not participated in this study and I 
have not taken  part in another study within the last 30 days prior to the start 
of the study. 
I received one original of the Patient Information Sheet together with the 
signed Information Consent Form. 
_____________________________________________________________ 
( Place, Date & Signature of the Patient) 
_____________________________________________________________ 
( Place, Date & Signature of the Doctor) 
                                PATIENT INFORMATION SHEET 
Who can be contacted for further questions? 
 
For further questions regarding this clinical study or your rights as patient 
and participant in the study, please contact your doctor who will always be 
ready to provide you the necessary information. 
 
If you have experienced any health related problems as well as in case of 
hospitalization please contact your doctor. 
Name and Address of the Contact Person:  
_____________________________________________________________ 
_____________________________________________________________ 
Phone number: ________________________________________________                   
 
          Please take a copy of this information sheet home with you. 
 
          
            INFORMED WRITTEN CONSENT FORM  IN TAMIL 
         ந ோயோளிகளி் தகவ் ம்ு் ஒ்ுத் பிவ் 
மோ்பக  ு்ுந ோயோளிகு்ு டோ்நசோூபிசி் 
 சிகி்சசயினோ்  இுதய்தி்  ஏ்பு் போதி்ுகசள   
எனலோபி ்  மு்தி்  ூல் து்பு ப்றிய ஆ்ு 
ந ோயோளி  அடையோள்பு்ுத்  : 
ப்நே்போள்  எ்  : 
ஒு ஆரோ்்சி ஆ்வி்  ப்நே்ு்பி  ீ்ே் 
நே்ு்கேோ்ள்புேிறீ் ே்.ப்ு கபற உ்ேு்ு விு்பமோ 
,எ்படத  ுிு கச்ய உ்ேு்ு உதவ இ்த்பிவ் தேவ்ேடள் 
கேோ்ு்ளு.ந ர் எு்ு்கேோ்ு ,இ்த பிவ்டத ேவனமோே 
பி்ு உ்ேு்ு இு்ு் ஐய்போுேடள ஆ்ு மு்ுவடரநயோ 
அ்லு ஏுு் ஊழிய்ேடளநயோ நே்ேு். 
இ்த ஆ்சவ ப்றி :- 
இ்த ஆ்வி் ப்நே்ே  ீ்ே் அுமதி்ே்புவத்ு இ்த 
ேோரண்ே் இு்ே்ூு் . 
 தோ்ே் மோ்பே் ு்ுந ோ்்ேோே  ைோ்நசோூபிசி்   சிேி்டச 
எு்ு்கேோ்வதோ் ஏ்பைநபோு்   இதய போதி்டப 
ு்ூ்ிநய அறி்ு கேோ்ளு் அதடன்  
து்பத்ேோன வழிுடறேடள பி்ப்ுவத்்ேோேு். 
 ோ் எ்ன சச்ுமோு நக்ுசகோ்ள்புநவ் . 
  
 ூ்ு  வோர்தி்ு ஒு ுடற வ்ு மோ்திடரேடள 
வோ்ேி்கேோ்வு . 
 ந ர்தி்ு சியோே ு்ுவு. 
 மு்ுவ் அறிுடர இ்லோம் எ்த ஒு ுதிய மு்நதோ 
மோ்திடரநயோ உ்கேோ்ளோம் இு்பு .  
  ீ்ே் ஒ்கவோு ுடற வு்கபோுு்  ீ்ே் எு்தமு்தி் 
ேோலிஅ்டைேடள கேோ்ுவுவு . 
 வுடேயி் இடையி் உ்ேு்ு ஏநது் ப்ேவிடளுே் 
இு்ேிறதோ எ்படத அறி்ு கேோ்வத்ேோே, ஆ்ு 
ஊழிய்ேளிைமிு்ு வு் கதோடலநபசி அடழ்ுேடள 
கப்ுகேோ்வு.  
 
 
 
ப்நக்பத்கோன துதிக் :- 
 ு்ுந ோ்   மு்ுவ்பி வி்  
உ்ந ோயோளியோே அுமதி்ே்ப்ு    ைோ்நசோூபிசி் 
 சிேி்டசகபு்   மோ்பே ு்ுந ோயளிே் ம்ு்.  
 
கீ்்க்டவ்ு் ஏநது் ுசறபோு உ்களிட் இு்தோ் 
 ீ்க் இ்த ஆ்வி் இு்ு வில்க்புவ ீ் க்:- 
 உ்ே் வயு 20்ு ேீழிு்தோ் ம்ு் 65 ்ு நமலிு்தோ்   
 ே்்பிணி ம்ு் போூ்ு் தோ்மோ்ே் 
 ே்ீர் ுடறபோு உடையவ்ே் 
 சிு ீரே் நேோளோு உடையவ்ே் 
 மு்தினோ் ஏ்பு் ஒ்வோடம. 
 இுுறு் சிு ீரே்   தமனி் ுு்ே் உடையவ்ே் 
  உய் இர்த அு்த் ம்ு் இதய ந ோயோளிே் 
  இர்த்தி் அதிேமோன கபோ்ைசிய் இு்பு 
 ீ்க் உ்க் ஆ்ு வுசககு்ு வு்நபோு ஆ்ு 
மு்ுவரோ் அ்லு ஆ்ு ஊழிய்களோ் பி்வுபசவகளி் 
ஏுு் ஒ்நறோ இ்சல ுுவுமோகநவோ உ்பு்தபுவ ீ் க். 
 உ்ே் மு்ுவ வரலோ்டற முஆ்ு கச்வு. 
 ஆ்ு மு்ுேடளு் அறிுடரேடளு் வழ்ுவு. 
 உ்ேளு இதய்ுி்ு ,இர்தஅு்த் ,உை்எடை,உயர்  
ஆேியவ்டற அள்பு . 
 இர்த் ம்ு் சிு ீ் மோதி ே் பிநசோதடன. 
 எகல்்நரோ ேோ்ிநயோ்ரோ் ( இுதய ுு் பை் ), ம்ு் 
எ்நேோேோ்ிநயோ்ரோ் ( இுதய ்நே் ). 
 
மு்ுக் எ்சபோுதோவு கீ்்க்ட பி்விசளுகசளநயோ 
அ்லு ப்கவிசளுகசளநயோ உ்டோ்கலோ். 
 வோ்தி,மய்ே். 
 க ்ுபைபை்ு , தடல ு்ற் . 
 இர்த்தி் அதிேமோன கபோ்ைசிய் இு்பு.  
 நதோலி் ஒ்வோடம.  
 எு்ும்டை  போதி்போ்  இர்தஅு்ே் ுடறவு  
 வோ்்ு்,  
 ுி உதி்ு  
 வற்ு இும்  
 ுே் ம்ு் உது வ ீ் ே்  
 இர்த அு்த் ுடறத்  
 ுடவயி் மோ்ற்  
 
     ஆ்வி் நபோு பி்விடளுே் ஏ்்ப்ைோ் ஆ்ு மு்ு 
உ்கேோ்வடத  ிு்திவி்ு உைனியோே மு்ுவடர 
அுேநவ்ு்.உ்ே் மு்ுவ் நவு மு்ு கேோு்ு 
பி்விடளுேடள  ிு்த ுய்சி்போ். 
 
இர்த் பிநசோதசன சச்வதோ் உ்டோு் எதி்விசளுக் 
 கபு்போலோனவ்ேு்ு இர்த் எு்பத்ேோே ஊசி ு்ுவு 
எ்வித நமோசமோன பிர்சடனேடளு் ஏ்பு்ுவதி்டல.ஆயிு் , 
சில ந ர்ேளி் இர்த் எு்ே்ப்ை இை்தி் , இர்த் ேசிு , இர்த் 
ே்றி் நபோத் ,அகசௌேிய் , ந ோ்கதோ்ு்ே் ம்ு் /அ்லு வலி 
ஆேியடவ உ்ைோேலோ். ீ்ே் தடலு்ுவதோேு் உணரலோ் 
 
எல்நரோகோ்ிநயோ்ரோ் / ஈ . சி . ஜி 
  எல்நரோேோ்ிநயோ்ரோ் / ஈசிைி பிநசோதடன இதய்ுி்ு 
அ்லு இதய தோள்தி் மி்சோர தைமறித்.அடவ ஈநேைி பிநசோதடன 
எனு் அடழ்ேபுேி்றன. ஈசிைி பிநசோதடன கச்ு கேோ்வத்ு , 
உ்ே் உைலி் ப்நவு புதிேளி் ஒ்ு்ே் டவ்ே்பு். 
 
எ்நகோ கோ்ிநயோ்ரோ் . 
எ்நேோ பிநசோதடன கச்வத்ு உ்ே் உைலி் க ்ு் புதியி் 
ிரோ்்ூச் எு் சிறிய ேுவி கேோ்ு ஆ்ு கச்ய்பு் 
.எ்நேோ  ேுவியிலிு்ு  எ்விதமோனஅபோயமோன அயனியோ்ு்ேதி்வ ீ
்ு்  உ்ைோவதி்டல.எ்நேோ ேுவியோனு மீகயோலி எு்பி அதடன 
 உைலி் கசு்திபி் அத் எதிகரோலி்டப ேண்ேி்ு இுதய 
தடசயி் த்டமடய ம்ு் இதய தடச   ிடற ுியீ் ுகய் 
ஆேியவ்டற அளவிை உது். 
  
உலகளோவிய தருக் போுகோ்ு அறி்சக 
 இ்த ஆ்டவ  ை்ுவத் ஒு புதியோே, உ்ே் மு்ுவ் 
தேவ்ேடள ஆ்ு மு்ுவ் தவிர பிறுை் பேி்்ு கேோ்வு 
அவசியமோேிறு. உ்ே் தனி்ப்ை ஆநரோ்ேிய் தேவ்ே் எ்வோு 
பய்பு்த்பு் ம்ு் இ்த ஆரோ்்சி ஆ்ு்ேோே அடவ யோு்ு் 
தர்பு் (கவளி்பு்ுத்) எ்படவ ப்றி, தருே் போுேோ்ு 
அறி்டே விள்ேமளி்ேிறு. உ்ே் தனி்ப்ை ஆநரோ்ேிய் 
தேவ்ேடள் போ்டவயிை உ்ே் உிடமே் உ்பை உ்ேளு 
போுேோ்ு உிடமேடளு் இு விவி்ேிறு. 
  ீ்ே் யோ் எ்ு ே்ைறிய் பய்பு்தபு் உ்ேடள் ப்றிய 
தேவ்ேநள உ்ே் தனி்ப்ை ஆநரோ்ேிய் தேவ்ேளோு். இ்த 
ஆ்வி்ு் நதடவ்பு் த்நபோடதய உ்ே் மு்ுவ் 
பதிநவுேளி் உ்ள தேவ்ே் இ்த ஆ்வி்நபோு உுவோ்ே்பு் 
அ்லு நசேி்ே்பு் ுதிய தேவ்ே் ஆேியவ்டற 
உ்ளை்ேியடவநய இ்த ஆ்வி்ு் நதடவயோன தேவ்ேளோு். 
 இ்த ஆ்வி்ேோன ஒ்ுத் பிவ்தி் டேகயோ்பமிுவத் 
வோயிலோே , இ்த தருே் போுேோ்ு அறி்டேயி் விவி்ே்ப்ு்ள 
உ்ே் தனி்ப்ை ஆநரோ்ேிய் தேவ்ேடள பய்போ்ு்ு் 
கவளி்பு்ுது்ு்  ீ்ே் அுமதி ;“அ்ேீேோர் “Ϳ அளி்ேிறீ் ே் . 
இ்பய்போுேடள  ீ்ே் அுமதி்ே விு்பவி்டல எ்றோ், இ்த 
ஆ்வி் ீ்ே் ப்நே்ே் ூைோு. 
 இ்த ஆ்வி் ப்நே்ே  ீ்ே் ஒ்ு் கேோ்ைோ், உ்ே் 
தனி்ப்ை ஆநரோ்ேிய் தேவ்ே் ேீ்்ே்ை வழிேளி் 
பய்பு்த்பு் ம்ு் கவளி்பு்த்பு். 
 ஆ்வி் நபோு, ஆ்டவ  ை்ுவத்ேோே, உ்ே் மு்ுவ் 
பதிநவுேடளு், உுவோ்ே்ப்ை அ்லு நசேி்ே்ப்ை 
தேவ்ேடளு் ஆ்ு மு்ுவ் ம்ு் ஊழிய்ே் 
பய்பு்ுவோ்ே். 
 ஒ்ுத் பிவ்தி் விவி்ே்ப்ை ஆ்வி் அறிவிய் 
ந ோ்ே்ேு்ு ஆதரவளி்ு் ஆரோ்்சி் ேோரண்ேு்ேோேு் 
,ஆ்வி் நச்்ே்ப்ை மு்ு அ்லு சிேி்டசயி் போுேோ்ு 
ம்ு் பல்ேடள மதி்புீ கச்யு், ஆ்வி் 
நச்்ே்ப்ு்ள ந ோ்(ே்) ப்றி சிற்போே ுி்ு கேோ்ளு் 
அ்லு எதி்ேோல ஆ்ுேடள விவடம்ு நம்பு்து் இ்த 
ஆ்ு் தருே் பய்பு். 
 உ்ேடள அடையோள் ேோணோத ஆ்ு் தருே் மு்ுவ 
இத்ேளி் கவளியிை்பைலோ் அ்லு அறிவிய் 
விவோத்ேளி் ஒு புதியோே ம்றவ்ேுை் பேி்்ு 
கேோ்ள்பைலோ். 
 உ்ே் மு்ுவ பதிநவுே் ம்ு் ஆ்ு் தருே் 
ேணினிேளி் டவ்ே்ப்ு கசய்ுடற்பு்த்பைலோ். 
 ஆ்ு கதோை்போன உ்ே் தனி்ப்ை ஆநரோ்ேிய் தேவ்ே், ஆ்ு 
மு்ுவிை் இு்ு்வடர, அவ்டற  ீ்ே் போ்டவயிைு் 
அவ்றி்  ேடல் கபறு், உ்ேு்ு உிடமு்ு. இு்பிு் 
,ஆ்வி் அறிவிய் ஒுடம்போ்டை உுதிகச்ு் கபோு்ு, ஆ்ு 
ுிவடைு் வடர சில ஆ்ு் தேவ்ேடள  ீ்ே் முஆ்ு கச்ய 
ுியோு. 
 ஆ்ு மு்ுவு்ு எு்ு ூல் அறிவி்டப அளி்ு உ்ே் 
அ்ேீேோர்டத எ்நபோு நவ்ுமோனோு்  ீ்ேி விைலோ்.  ீ்ே் 
உ்ே் அ்ேீேோர்டத  ீ்ேி் கேோ்ைோ், ஆ்வி் அறிவிய் 
ஒுடம்போ்டை போுேோ்பத்ேோே, ஆ்ு மு்ுவ் அ்லு 
ஊழிய்ே் இ்த ஆ்ுை் கதோை்ுடைய உ்ே் தனி்ப்ை மு்ுவ் 
தேவ்ே் சிலவ்டற பய்பு்ு் அ்லு உிடம வழ்ே் நதடவ 
இ்லோதவடர , உ்ே் ஆ்ு மு்ுவ் அ்லு ஊழிய்ே் உ்ே் 
தனி்ப்ை ஆநரோ்ேிய் தேவ்ேடள் பய்பு்தநவோ அ்லு 
கவளி்பு்தநவோ மோ்ைோ்ே்.  
                                                                     
                                                                இசை்ு - 2 
             ந ோயோளி தகவ் ம்ு் ஒ்ுத் பிவ்  
          ஆ்விட் தகவ் ம்ு் சதோட்ு விவர்க் 
மோ்பக  ு்ுந ோயோளிகு்ு டோ்நசோூபிசி் சிகி்சசயினோ்   
இுதய்தி் ஏ்பு் போதி்ுகசள  எனலோபி ் மு்தி்  ூல் 
து்பு ப்றிய ஆ்ு. 
 
ஆ்ு ுறி்த ஐய்போுக் ம்ு்  விவர்கசள் ப்றி 
நக்பத்கோன ஆ்ு மு்ுவ்களி் சதோட்ு விவர்க். 
ஆ்ு மு்ுவி் சபய் :-            
_________________________________________________ 
ுேவி :-                            
_____________________________________________________________ 
______________________________________________________________________________ 
கதோை்ு எ் :-  
___________________________________________________________________               
 
 ஓ் ப்நக்போளரோக உ்க் உிசமகசள் ப்றி நக்பத்கோன 
ஈஆ்பி சதோட்ு விவர்க் :- 
ஐஆ்பி சதோட்ு பி் சபய் :- 
___________________________________________________ 
______________________________________________________________________________ 
கதோை்ு எ் :- 
____________________________________________________________________                       
                                                                            இசை்ு -3. 
              ந ோயோளி தகவ் ம்ு் ஒ்ுத் பிவ்   
மோ்பக  ு்ுந ோயோளிகு்ு டோ்நசோூபிசி்  சிகி்சசயினோ்   
இுதய்தி் ஏ்பு் போதி்ுகசள  எனலோபி ்  மு்தி்  ூல் 
து்பு ப்றிய ஆ்ு 
 
இ்த் ப்ே்தி் டேகயோ்பமிுவத் ூலமோே ,பி்வுவனவ்டற 
 ோ் உுதி கச்ேிநற். 
 நம்பி ஆ்வி்ேோன ___________________      நததியிை்ப்ை இ்த 
ந ோயோளி தேவ் ம்ு் ஒ்ுத் பிவ்திு்ள அடன்ு் 
தேவ்ேடளு்  ோ் பி்ு் ுி்ு கேோ்ிு்ேிநற் எனு் 
அடத்ப்றி சி்தி்ே என்ு ேோல அவேோச் இு்து எனு் 
 ோ் உுதியளி்ேிநற். 
 நே்விே் நே்பத்ேோன வோ்்ு என்ு இு்து நமு் எனு 
நே்விேளடன்ு் எனு திு்தி்ு் த்ேவோு 
பதிலளி்ே்ப்ிு்ேி்றன. 
 இ்த ஆ்வி் எ் ப்நே்ு த்னோ்வ் சோ்்து எனு் 
ப்நே்டப எ்நபோு நவ்ுமோனோு் எ்வித் ேோரணு் 
அளி்ேோம், எ் மு்ுவ் ேவனி்ு அ்லு ச்ை உிடமே் 
போதி்ே்பைோம் விலேி் கேோ்ள  ோ் ுத்திரமோனவ் எ்படத 
 ோ் ுி்ு கேோ்ேிநற். 
 நவ்ி்கேோ்ள்ப்ைபி, ஆ்ு  டைுடறேடள பி்ப்று் 
,ம்ு் மு்ுவ் ,கசவிலிே் ,அ்லு ம்ற ஊழிய 
உு்பின்ேு்ு நதடவயோன தேவ்ேடள வழ்ேு்  ோ் 
த்னோ்வ்ுை் ஒ்ு் கேோ்ேிநற். 
 இ்த ஆ்விலிு்ு எு் எ்தகவோு தரு அ்லு ுிுேளி் 
உபநயோே்திடனு்,இு நபோ்ற உபநயோேமோன தரு போுேோ்ு 
அறி்டேயி் ுறி்பி்ைபி ம்ுமோே உபநயோேி்ே்பு் 
ப்ச்தி் அடவேடள  ோ் து்ேோமலிு்ே  ோ் ஒ்ு் 
கேோ்ேிநற். 
 நம்ே்ை ஆ்வி் ப்கேு்ே ோ் ஒ்ு் கேோ்ேிநற். 
 என்ேோே டவ்ு்கேோ்வத்ேோே இ்த ந ோயோளி தேவ் ம்ு் 
ஒ்ுத் பிவ்தி் ஓ் ேடல ோ் கப்ு் கேோ்ேிநற். 
 
நததி:- 
ந ோயோளி / ச்ைூ்வமோே ஏ்ு்             (அ்லு)         ந ோயோளி 
ே்ேோதவரோனோ்   
கேோ்ள்ூிய பிரதி ிதியி்(எ்ஏஆ்)                   
(ந ோயோளி/எ்ஏஆ்)தோமோேநவ       
டேகயோ்ப்                                       போுபோை்ற சோ்சியி் ு்னிடலயி் 
நததியிை   நவ்ு்) 
       
ந ோயோளி வோ்ூலமோன ஒ்ுத் 
கேோு்திு்ேிறோ் எ்படத ுறி்பத்ேோே 
கபுவிர் நரடே) 
 
ந ோயோளி கபய்:-                          
ந ோயோளி எ் ம்ு் கபய் ுதகலு்ு்ே் 
பிற்த நததி  & வயு:- 
எ்ஏஆ்-இ் கபய் ,உி்தோனோ் 
(அ்சி் அ்லு த்ை்சி்) 
ச்ை்ூ்வமோே ஏ்ு்கேோ்ள்ூிய 
பிரதி ிதி டேகயோ்பமி்ைோ், 
ந ோயோளிுைனோன உறுுடற. 
தேவலளி்ே்ப்ை ஒ்ுத் விவர்டத 
 ை்ு் ஆரோ்்சியோள் / அவரோ் 
 ியமி்ே்ப்ைவி் கபய்(அ்சி் அ்லு 
த்ை்சி்).                                                                                       
                            
 
 
 
 
 
 
 
                                                                                MASTERT CHARTS 
CONTROL  GROUP ( WITHOUT ENALAPRIL) 
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1 71892 45 F 166 68 1.8 540 0.2 1.5 1.7 64 60 58 54 48 35 32 30 27 25 
2 71907 48 F 158 54 1.5 450 0.4 0.5 0.5 63 61 59 60 60 34 32 31 31 32 
3 71893 43 F 157 55 1.5 450 0.1 0.1 0.1 61 60 57 58 57 33 32 30 30 30 
4 71871 38 F 163 58 1.6 480 0.2 0.2 0.3 58 58 56 55 54 30 30 29 28 28 
5 71870 64 F 154 60 1.6 480 0.3 0.5 0.5 62 60 59 57 57 34 33 32 31 31 
6 71913 58 F 164 70 1.8 540 0.4 1.7 2.1 61 57 54 52 47 34 31 29 28 25 
7 71868 59 F 165 52 1.5 450 0.1 0.2 0.2 60 59 58 57 57 33 32 31 30 30 
8 82772 55 F 156 60 1.6 480 0.2 0.2 0.3 62 61 59 57 58 34 33 31 30 31 
9 82998 49 F 166 53 1.5 450 0.2 0.3 0.4 64 62 60 60 58 36 34 32 32 31 
10 83015 35 F 155 62 1.6 480 0.4 0.3 0.3 69 67 65 64 64 40 38 35 35 36 
11 82997 64 F 161 62 1.7 510 0.5 1.7 2.2 62 59 55 53 48 35 33 30 28 25 
12 83006 39 F 154 54 1.6 480 0.3 0.4 0.4 60 58 56 55 57 33 32 31 30 31 
13 83007 65 F 151 52 1.5 450 0.4 0.4 0.3 61 59 58 57 57 33 32 31 30 30 
14 83034 57 F 152 50 1.5 450 0.2 0.3 0.2 60 58 56 57 57 33 31 31 31 30 
15 83000 60 F 166 56 1.6 480 0.4 0.3 0.3 59 56 55 55 55 32 30 29 29 28 
16 83026 49 F 158 50 1.5 450 0.3 0.3 0.4 61 58 58 57 57 33 32 32 30 30 
17 73708 54 F 155 57 1.6 480 0.2 0.2 0.3 63 60 60 59 60 35 33 34 32 33 
18 66840 65 F 156 68 1.7 510 0.4 1.3 1.7 58 53 50 48 45 31 28 27 25 24 
19 68724 63 F 168 74 1.9 570 0.5 1.4 1.8 58 55 52 49 46 31 29 27 26 24 
20 66820 34 F 148 53 1.5 450 0.1 0.2 0.2 70 68 66 66 66 40 38 37 36 36 
21 66839 50 F 150 50 1.4 420 0.1 0.1 0.2 58 57 54 54 54 32 32 31 30 29 
22 66724 52 F 165 70 1.8 540 0.4 1.4 1.9 61 55 52 49 47 33 30 28 27 24 
23 82982 64 F 159 57 1.6 480 0.1 0.1 0.2 63 61 60 59 60 35 33 32 31 32 
24 82986 60 F 166 66 1.7 510 0.4 1.4 1.7 59 55 53 52 46 32 30 29 27 25 
25 82983 54 F 158 52 1.5 450 0.2 0.2 0.2 66 63 61 62 62 36 35 33 33 33 
26 82990 58 F 160 56 1.6 480 0.1 0.1 0.2 58 54 52 54 52 31 30 29 29 28 
27 82957 55 F 153 54 1.5 450 0.2 0.2 0.3 65 63 60 61 60 35 33 32 31 31 
28 73718 61 F 162 70 1.8 540 0.5 1.5 1.9 60 57 55 51 48 33 30 29 26 25 
29 66831 37 F 158 60 1.6 480 0.3 0.3 0.4 62 57 54 53 52 33 30 29 28 27 
30 66729 65 F 160 70 1.8 540 0.5 1.6 1.9 61 55 53 53 48 33 29 28 27 25 
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1 63806 64 F 160 62 1.7 510 0.2 1.4 1.3 63 57 55 61 64 34 30 29 32 34 
2 64852 62 F 155 58 1.6 480 0.1 0.2 0.2 65 63 63 66 66 38 36 35 37 38 
3 64775 45 F 150 55 1.5 450 0.1 0.2 0.2 67 65 65 66 68 38 36 37 38 39 
4 64795 60 F 156 60 1.6 480 0.3 1.4 1.2 64 60 57 65 65 35 33 30 34 35 
5 64771 63 F 158 65 1.7 510 0.1 1.5 1.7 60 55 53 61 62 34 29 28 32 34 
6 64796 62 F 162 70 1.8 540 0.3 1.8 1.5 58 52 48 60 61 33 31 25 31 32 
7 64740 55 F 165 56 1.6 480 0.2 0.2 0.2 59 60 58 61 62 30 30 31 32 33 
8 64738 45 F 159 62 1.6 480 0.1 0.1 0.1 65 63 62 65 66 36 34 33 34 35 
9 64734 58 F 164 70 1.8 540 0.4 0.4 0.4 58 56 54 59 61 33 32 31 32 34 
10 64752 35 F 155 60 1.6 480 0.5 0.5 0.5 60 58 58 60 62 33 32 32 33 33 
11 70842 42 F 158 62 1.6 480 0.5 0.5 0.5 62 59 58 60 63 36 35 34 33 34 
12 70843 50 F 156 58 1.6 480 0.2 0.3 0.3 59 57 57 58 60 33 32 31 32 33 
13 70870 36 F 154 52 1.5 450 0.3 0.3 0.3 61 60 58 60 60 33 32 32 32 33 
  
14 70846 40 F 152 64 1.6 480 0.3 0.3 0.3 66 63 62 63 65 36 34 34 38 38 
15 78190 61 F 165 74 1.9 570 0.2 2.2 1.7 58 53 47 56 60 31 29 25 29 31 
16 74340 57 F 160 58 1.6 480 0.3 0.3 0.3 65 62 61 62 62 38 37 37 39 38 
17 79146 48 F 154 50 1.5 450 0.1 0.1 0.1 60 60 56 58 58 33 32 30 31 31 
18 79142 58 F 158 54 1.5 450 0.1 0.1 0.1 57 56 54 56 60 30 30 29 31 31 
19 79129 52 F 156 60 1.6 480 0.2 0.5 0.5 64 61 55 60 61 37 35 30 35 37 
20 79127 64 F 162 64 1.7 510 0.3 1.9 1.9 59 54 50 58 59 32 31 26 31 32 
21 75176 55 F 158 60 1.6 480 0.1 0.2 0.2 62 60 58 60 61 33 33 31 33 33 
22 79125 53 F 152 55 1.5 450 0.2 0.2 0.2 58 55 53 55 58 31 30 28 31 31 
23 79143 60 F 162 58 1.6 480 0.4 0.7 0.7 63 61 57 60 62 37 33 32 34 35 
24 79168 65 F 160 63 1.7 510 0.2 1.4 1.4 64 58 54 60 62 36 33 30 33 35 
25 79138 38 F 156 58 1.6 480 0.2 0.2 0.2 58 58 56 56 60 32 32 30 31 33 
26 79128 36 F 156 54 1.5 450 0.4 0.4 0.4 60 58 56 59 61 33 31 30 31 33 
27 79136 57 F 154 62 1.6 480 0.4 0.7 0.9 63 61 59 61 62 34 32 32 33 34 
28 79169 61 F 160 66 1.7 510 0.5 1.1 1.1 62 58 56 59 62 33 30 29 28 33 
29 78170 35 F 158 58 1.6 480 0.3 0.3 0.3 60 59 58 58 61 33 31 31 32 34 
30 78185 47 F 154 60 1.6 480 0.1 0.7 0.7 64 62 61 63 63 36 32 31 34 36 
                                ABBREVIATIONS 
 
ACE 
ACEI 
AIP 
ALL 
AML 
ARB 
AT1 R 
ATP 
CAD 
CHF 
CLL 
CT 
DNA 
DOX 
ECG 
ECHO 
EDV 
ELISA 
ESV 
FDA 
FGF 
FNAC 
 
-Angiotensin converting enzyme 
-Angiotensin converting enzyme inhibitor 
-Aldosterone induced protein 
-Acute lymphoblastic leukemia 
-Acute myeloblastic leukemia 
-Angiotensin receptor blocker 
-Angiotensin 1 receptor 
-Adenosine tri phosphate 
-Coronary artery disease 
-Congestive heart failure 
-Chronic lymphoblastic leukemia 
-Computed tomography 
-Deoxyribonucleic acid 
-Doxorubicin 
-Electrocardiogram 
-Echocardiogram 
-End diastolic volume 
- Enzyme-linked immunosorbent  assay 
-End systolic volume 
-Food and drug administration 
-Fibroblast growth factor 
-Fine needle aspiration cytology 
FS 
HSP 
IRP 
IUGR 
LVEF 
LVIDd 
LVIDs 
MAPK 
MRI 
NADPH 
NOS 
NSAID 
PDGF 
RAS 
RNA 
ROS 
sNAP 
SOD 
TGF 
TnI 
VT 
WHO 
5 FU 
 
-Fractional shortening 
-Heat shock protein 
-Iron regulatory proteins 
-Intra uterine growth retardation 
-Left ventricular ejection fraction 
-Left ventricular internal diameter in diastole 
-Left ventricular internal diameter in systole 
-Mitogen activated protein kinase 
-Magnetic resonance imaging 
-Nicotinamide adenine dinucleotide phosphate 
-Nitric oxide synthase 
-Non steroidal antiinflammatory drugs 
-Platelet derived growth factor 
-Renin angiotensin system 
-Ribonucleic acid 
-Reactive oxygen species 
-s-Nitrosyl n- acetyl penicillamine 
-Super oxide dismutase 
-Transforming growth factor 
-Troponin I 
-Ventricular tachycardia 
-World health organization 
-5 Fluorouracil 
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